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Abstract: 
Introduction: Surgery is considered the only curative treatment for resectable esophageal carcinoma 
with improving results over the last decades. Aim of the present retrospective, single- center analysis 
was to identify potential factors influencing postoperative morbidity and survival in patients with 
esophageal carcinoma subjected to surgical therapy 
 
Patients and Methods: Patients who underwent surgery for esophageal cancer at the University 
Clinic of Saarland between 01.01.2001 and 31.12.2014 were included. Primary end points were 
postoperative morbidity and overall survival (OS) after esophagectomy. Patient- and tumor- related 
properties, operative and postoperative data were included in the analysis. Statistical analysis was 
performed using χ² test and binary logistic regression in case of categorical variables and Mann-
Whitney U test in case of non- parametric, not normally distributed continuous variables. The 
distribution of continuous variables was tested with Kolmogorov- Smirnov test. Statistical significance 
was set at p≤ 0.05. Survival data were recorded by the Cancer Registry of Saarland or the house 
doctors, respectively. A 6 months’ follow- up was routinely performed including endoscopy. Log rank 
test and Cox- regression were performed for survival analysis. Statistical analysis was conducted in 
IBM SPSS Statistics V22.0. 
 
Results: 320 patients with esophageal cancer were treated in the University Clinic of Saarland from 
01.01.2001 and 31.12.2014. Men/ women ratio was 268:52 (83.8%:16.2%), median age of patients at 
time of operation was 63 years (28- 88 years). More than half of the patients (n=179) were subjected 
to abdomino- thoracic esophageal resection (TAE) with intrathoracic anastomosis (55.9%). Transhiatal 
esophagectomy (THE) with intraabdominal anastomosis was performed in 59 patients (18.4 %), 
abdomino- thoracic esophageal resection with cervical anastomosis in 52 patients (16.3 %), and 
transhiatal esophagectomy with cervical anastomosis in 30 patients (9.4 %), respectively. In 222 
patients (69.4 %) a hand- sewn, double- row, end- to- end anastomosis was performed, whereas 98 
patients received a stapled, end- to- side anastomosis (30.6 %). Median overall survival was 17 
months (0, 146.5 months). The 1-, 3- and 5 –year survival rates were 65.2%, 41.7%, and 30.7%, 
respectively. The 30-, 60- and 90- day mortality rate was 5.9% (19/320), 9.4% (37/320), and 12.8% 
(41/320), respectively.  
 
12.5% (40/320) of patients had a minor postoperative complication (Clavien- Dindo grade I- II).  
26.9% (86/320) of patients experienced a major postoperative complication (Clavien- Dindo grade III- 
IV), thus requiring surgical, endoscopic or radiological intervention or management in Intensive Care 
Unit (ICU). 12.8% (41/320) of patients had a lethal postoperative complication (Clavien- Dindo grade 
V). In 47.8% (153/320) of patients, the postoperative course was uneventful. 
5 
 
 
 
 
Advanced tumor stage, SC histological subtype and presence of major or lethal postoperative 
complications Clavien- Dindo grade III- V were significant, independent factors for worse OS (p< 
0.001, OR= 0.239, p= 0.028, OR= 1.506, and p= 0.005, OR= 0.582, respectively). 
 
Female gender, anastomotic leak and respiratory complications were significant, independent factors 
for higher rate of major and lethal postoperative complications (Clavien- Dindo III- V) after resection 
for esophageal cancer in the multivariate regression analysis with p= 0.002, OR= 0.417, p< 0.001, 
OR= 0.028, and p< 0.001, OR= 0.121 respectively. 
 
Anastomotic leak was significantly related with presence of COPD (p= 0.026, OR= 2.109, 95% CI= 
1.096- 4.061. Neoadjuvant therapy, surgical experience, type of surgery and type of anastomosis did 
not significantly influence the rate of anastomotic leak (p= 0.853, OR= 0.942, p= 0.274, OR= 1.264, 
p= 0.893, OR= 1.023, and p= 0.471, OR= 0.772, respectively). 
 
Intrathoracic stapler anastomosis as part of an abdomino-thoracic esophageal resection rendered better 
postoperative results (n=176), in terms of anastomotic leak and stricture, in comparison to hand- sewn 
anastomosis (8% vs. 14.3%, p= 0.22, 6% vs. 13.5%, p= 0.10, respectively), however not reaching 
statistical significance. In addition, 90- day mortality was significantly lower in the stapler 
anastomosis group (2% vs. 13.5%, p= 0.02 respectively), due to the higher rate of reoperations in the 
hand- sewn anastomosis group (8% vs. 34.1%, p= 0.001). 
 
 
Conclusions:  
Esophageal surgery for cancer is associated with a high risk for major surgical complication. 
Advanced tumor stage, histological subtype (squamous cell carcinoma), and major or lethal 
postoperative complications Clavien- Dindo grade III- V were significant, independent factors for 
worse OS after resection for esophageal cancer. In conclusion, any efforts improving surgical 
performance are mandatory, since continuous improvements in this field will result in a better patient 
outcome. 
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1. Introduction: 
 
1.1 Epidemiology.  
The squamous- cell esophageal carcinoma is worldwide the most frequent histological type of 
esophageal tumor. The incidence varies in different geographical areas. Areas with high 
incidence rates of esophageal cancer are Iran, central China and South Africa with 200 new 
patients every year per 100.000 inhabitants. In the western countries however, esophageal 
adenocarcinoma is more frequently diagnosed than squamous- cell esophageal carcinoma.  
 
The incidence of esophageal cancer in Germany is about 4-5/ 100.000 residents in males, and 
0.5- 1/ 100.000 in female patients. Esophageal cancer was diagnosed in approximately 1.050 
women and 3.900 men in Germany according to the ―Robert Koch‖ institute in the year 2000 
(I). The median age of patients with esophageal cancer is 65 years.  70 % of patients with 
esophageal carcinoma are diagnosed with advanced tumor stages (UICC III and IV) ˡ.  
 
In Western countries, more than 80% of squamous-cell esophageal cancer (SCC) is associated 
with tobacco and alcohol consumption. Various predisposing factors for SCC were suggested 
in the past of which the most important are: Plummer- Vinson syndrome, celiac disease, 
sclerodermia, pernicious anemia, esophageal diverticuli, intoxication with acid and previous 
radiotherapy in the neck or the thorax ˡ. On the other hand, obesity, chronic reflux disease and 
intestinal (Barrett) metaplasy were identified to be risk factors for AEG ˡ.   
 
The adenocarcinomas of esophagus within 5 cm up and down the cardia are called 
adenocarcinomas of the gastroesophageal junction (AEG) according to international 
consensus.  
 
The 5-year overall survival of patients with esophageal cancer remains poor, reaching 5% in 
some reports 
1
. An increase of 5- year survival was however reported in Germany from 10% 
in 1980 to 20% in 2010, presumably due to the evolution of new therapeutic modalities (I). 
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1.2 TNM, UICC-, AEG- classification.  
The human esophagus has a mucosa consisting of a squamous epithelium without keratin, a 
smooth lamina propria, and a muscularis mucosae. Esophageal carcinoma is divided in 
squamous- cell carcinoma, adenocarcinoma and adenocarcinoma of the gastroesophageal 
junction (AEG). Adenocarcinoma of the esophagus may be related to acid reflux, resembling 
a disorder of the lower esophagus known as Barrett esophagus [B1]. The most recent TNM 
and UICC classification in its seventh edition dates from January 2010 and is presented in 
tables 1- 4 [I]. The changes in the actual TNM, UICC classification compared to previous 
staging systems are: the exact number of the infiltrated/ tumorous lymph nodes is recorded 
due to its prognostic value. N1 means 1-2 lymph node metastases, N2 means 3-6 lymph node 
metastases and N3 more than 6 lymph node metastases. The pathological specimen should 
include >6 lymph nodes (LN). Positive infraclavicular LN or positive LN of the celiac trunk 
are no longer considered distant metastases (M1, stage IV disease). Squamous- cell 
carcinoma, adenocarcinoma and adenocarcinoma of the esophageal junction (AEG) are all 
classified as esophageal carcinoma. The argumentation in favor of the new classification is 
based on the similar prognosis of AEG and esophageal carcinoma, which is worse compared 
to gastric carcinoma of other locations.  
 
The Siewert classification system is used for adenocarcinoma located at the gastro- 
esophageal junction. The junctional adenocarcinoma is divided into 3 subtypes 
2, 3
 (figure 1). 
The division is based upon the localization of the tumor center in relation to the cardia. The 
term cardia refers to the transition zone between the two- layer muscle of the esophageal and 
the three- layer muscle of the gastric wall. Cardia can precisely be identified only in the 
pathological specimen because the esophagus is not covered with serosa. The transition zone 
between squamous and cylindric esophageal epithel (Z-line) cannot be used to classify AEG, 
because the Z-line is subjected to changes in reflux disease (Barrett metaplasy). The 
transitional zone from esophagus to stomach can precisely be identified by endoscopy, where 
the proximal margin of gastric plication is the main point of orientation 
2
.   
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The 3 subtypes of AEG are: 
 AEG I:  The tumor center is localized until 5 cm orally from cardia. 
 AEG II:  The tumor center is localized directly in the cardia. 
 AEG III: The tumor center is localized below the cardia.  
The AEGs are divided according to Siewert et al. in 3 types 
2
 : the AEG  of type I is the 
distant esophageal adenocarcinoma arising from Barrett mucosa with contact to the Z- line. 
The AEG of type II is the carcinoma of the gastric cardia and the AEG of type III is the 
subcardial carcinoma, localized in the stomach but still being in contact with the Z- line. This 
classification has gained broad acceptance, because the type of surgery depends on the 
localization of the tumor with respect to the gastroesophageal junction. The various surgical 
procedures for esophageal cancer are thoroughly described below. 
 
Table 1. Primary tumor (T)
a,b
 
Tx Primary tumor cannot be assessed. 
T0 No evidence of primary tumor. 
Tis High-grade dysplasia. 
T1 Tumor invades lamina propria, muscularis mucosae, or submucosa. 
T1a Tumor invades lamina propria or muscularis mucosae. 
T1b Tumor invades submucosa. 
T2 Tumor invades muscularis propria. 
T3 Tumor invades adventitia. 
T4 Tumor invades adjacent structures. 
T4a Resectable tumor invading pleura, pericardium, or diaphragm. 
T4b Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, 
trachea, etc. 
a
(1) At least maximal dimension of the tumor must be recorded, and (2) multiple 
tumors require the T(m) suffix.  
b 
High-grade dysplasia includes all noninvasive neoplastic epithelia formerly 
called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae 
anywhere in the gastrointestinal tract.  
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Table 2. Regional lymph nodes (N)
a
 
 
Nx Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis. 
N1 Metastases in 1–2 regional lymph nodes. 
N2 Metastases in 3–6 regional lymph nodes. 
N3 Metastases in ≥7 regional lymph nodes 
a 
Number must be recorded for total number of regional nodes sampled and total number of 
reported nodes with metastasis. 
 
Table 3. Distant metastasis (M)  
M0 No distant metastasis. 
M1 Distant metastasis. 
 
Table 4. Histologic grade (G) 
Gx Grade cannot be assessed—stage grouping as G1 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated—stage grouping as G3 squamous 
 
                UICC Classification 
Stage    T N M Grade 
0 Tis 
(HGD) 
N0 M0 1, X 
IA            T1 N0 M0 1-2, X 
IB            T1 N0 M0 3 
             T2 N0 M0 1-2, X 
IIA            T2 N0 M0 3 
IIB            T3 N0 M0 Any 
           T1-2 N1 M0 Any 
IIIA          T1-2 N2 M0 Any 
  T3 N1 M0 Any 
  T4a N0 M0 Any 
IIIB T3 N2 M0 Any 
IIIC T4a N1-
2 
M0 Any 
  T4b Any M0 Any 
10 
 
 
  Any N3 M0 Any 
IV Any Any M1 Any 
 
 
Restrictions of the new TNM, UICC- staging system. The new staging system for 
esophageal cancer is mainly based on retrospective data from the Japanese committee for 
registration of esophageal cancer. It is therefore most applicable to patients with squamous 
cell carcinomas of the upper third and middle third of the esophagus in contrary to the 
increasingly common distal esophageal and gastroesophageal junction adenocarcinomas in 
Western countries 
4
.  
 
The lymph node involvement was revised in the new classification system; in particular, the 
previous characterization of involved abdominal lymph nodes as M1 disease was revised in 
the new classification system. Positive infraclavicular lymph nodes or positive lymph nodes 
of the celiac trunk are no longer classified as distant organ metastases (M1, stage IV disease). 
This change in the classification system indicates that tumorous infiltrated abdominal lymph 
nodes do not worsen the prognosis in contrast to remote organ metastases 
5
. This alteration in 
the new staging system led to more liberally indicating surgical treatment, as regional lymph 
node involvement and/or positive lymph nodes of the celiac trunk should not be considered 
irresectable. Complete resection of the primary tumor (R0 resection) and lymphadenectomy 
of tumor- involved lymph nodes should therefore be performed. 
 
 In the new TNM-system the adenocarcinoma of the esophagogastric junction (AEG) is 
classified similar to the esophageal carcinoma. The reason was the similar prognosis of AEG 
and esophageal carcinoma, which is worse than that of gastric carcinoma in other sites 
6
[4]. 
The TNM- Classification has both prognostic and therapeutic value. 
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Figure 1:  Topographic-anatomic classification of adenocarcinomas of the esophago–gastric junction (AEG) 
based on their relationship to the endoscopic gastric cardia.
3
. 
 
1.3 Diagnostic work- up. The preoperative diagnostic work- up includes an 
esophagogastroduodenoscopy with biopsy sampling, an endosonography and computed 
tomography (CT). The endoscopy plays a key role in diagnosing esophageal cancer; it 
provides preoperative information about the localization of the tumor and the tumor identity 
with the acquisition of specimen for histopathologic examination. In patients with dysphagia 
due to inoperable esophageal cancer or tumor recurrence, the enteral feeding of the patient 
can be enabled by percutaneous endoscopic gastrostomy (PEG). A PEG can also be used in 
patients who are no candidates for surgery because of cachexia to enhance the nutritial status 
before surgical treatment. 
 
In patients with positive lymph nodes, neoadjuvant treatment could be considered prior to 
surgery. The preoperative T- and N- stages are estimated with endosonography (EUS). 
Detection of tumor infiltration of lymph nodes in the preoperative endosonography may 
determine the therapeutic strategy.  Endoscopic ultrasound (EUS) can detect lesions of 
esophageal cancer and accurately determine the T stage. In a recent meta-analysis of EUS in 
esophageal cancer, sensitivity and specificity of EUS on esophageal cancer were 81.6% and 
99.4% in T1, 81.4% and 96.3% in T2, 91.4% and 94.4% in T3, and 92.4% and 97.4% in T4, 
12 
 
 
respectively 
7
. The opportunity of endoscopic submucosal dissection requires presurgical 
detection of early cancer lesions without lymph node metastases 
8
.  
 
Preoperative computed tomography (CT) is performed to detect remote organ metastases (M- 
stage) and to describe local infiltration of T4 tumors. 
9
. 
 
Some studies support the use of PET-CT to detect distant organ metastases 
10-14
. However, the 
value of 18F- FDG- PET- CT (fluorine-18 fluoro-2-deoxy-D-glucose-positron emission 
tomography combined with computed tomography) in the preoperative diagnostic work- up 
for esophageal cancer is currently under investigation. For example, the pre SANO trial  
investigates, whether FDG- PET- CT may accurately detect residual disease after neoadjuvant 
radiochemotherapy 
15
. In fact, FDG- PET was not used in our institution for preoperative 
diagnostic work- up, whereas preoperative evaluation of pulmonary and cardiologic function 
was frequently performed in order to estimate the patient´s perioperative risk. 
 
 
1.4 Therapeutic strategies. The therapy of esophageal cancer is interdisciplinary and 
depends on tumor stage and patient’s co- morbidities. Endoscopic therapy can be performed 
in patients with very early tumor stages (uT1a) and without lymph node involvement, whereas 
neoadjuvant treatment followed by surgical resection is usually performed in patients with 
advanced tumor stages (≥T3 and /or any N+) in the absence of distant organ metastases. The 
therapeutic plan is individually set for every patient within an interdisciplinary tumor board, 
in which surgeons, gastroenterologists, and radiotherapists take part. 
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1.4.1 Surgery for esophageal cancer.   
Various surgical procedures were used for esophageal cancer patients during the reported 
period, of which a brief history and description are presented in the following. 
S. Meltzer and J. Auer introduced the use of general anesthesia with positive- pressure 
ventilation under tracheal intubation in 1909 in the United States of America (USA) 
16
. This 
advance has allowed F. Torek to perform the first successful transthoracic esophageal 
resection for cancer with left thoracotomy under general anesthesia in the USA 
17
. Continuity 
of the gastrointestinal tract was provided by an external "rubber tube" that was put between 
the cervical esophagostomy and the gastrostomy. The patient has survived 13 years and was 
able to swallow liquid food. Direct reconstruction of the gastrointestinal tract after an 
esophagectomy with esophago -gastrostomy was performed in the mid- 1930s for the first 
time.  
The main surgical procedures performed in our department were: transhiatal esophagectomy 
(THE), Ivor- Lewis abdomino-thoracic esophagectomy with intrathoracic anastomosis, and 
Mc Kewon abdomino-thoracic esophagectomy with cervical anastomosis.  
 
Transhiatal esophagectomy (THE). The British surgeon G. G. Turner carried out the first 
successful transhiatal esophagectomy for cancer in 1933
18
. The continuity of the alimentary 
tract was reestabilished in a second operation using an antethoracic skin tube. In the following 
years, transhiatal esophagectomy without thoracotomy (THE) was performed only 
sporadically, usually as part of laryngopharyngoesophagectomy for pharyngeal or cervical 
esophageal carcinoma. The stomach was used to restore continuity of the alimentary tract. 
Kirk used this surgical procedure for palliation of unresectable esophageal carcinoma in 5 
patients. Orringer ―rediscovered‖ this technique for esophageal cancer in 1976. He supported 
THE because of avoidance of (1) combined thoracic and abdominal incisions in patients with 
esophageal obstruction and (2) a mediastinal anastomosis with its potential for mediastinitis 
due to leakage. In 2007, Orringer et al. retrospectively published the surgical results of THE 
in 2000 patients from 1976 until 2006 
18
. 
 
In the original procedure performed by Orringer in 1976, the esophagus was mobilized using 
two incisions, an upper abdominal incision and a second incision on the left side of the neck. 
14 
 
 
After removal of the esophagus, the remaining short segment of esophagus was attached to 
the stomach by means of a cervical esophagogastric anastomosis. An obvious advantage of 
the transhiatal esophagectomy is, that no opening of the thorax is required 
18
.    
 
The transhiatal esophagectomy was also performed in our institution. In this surgical 
procedure, the hiatus esophagei is opened and the distal esophagus is mobilized. The surgeon 
can estimate at this point, if the tumor is resectable without opening the thoracic cavity. In the 
transhiatal esophagectomy, the stomach may be used for interposition, the so called gastric 
tube, otherwise total gastrectomy with resection of the distal esophagus is performed. In the 
preparation of the stomach, the A. and V. gastroepiploica dextra are identified and then 
resected. In the middle of the major curvature, the A. gastroepiploica sinistra can be 
separated. Preparation of the major gastric curvature is followed by the preparation of the 
minor gastric curvature. The left gastric artery is dissected. Lymphadenectomy is 
standardized. D2 dissections (N2 level) add the removal of nodes along the left gastric artery 
(station 7), common hepatic artery (station 8), celiac trunk (station 9), splenic hilus, and 
splenic artery (station 10 and 11). The lymph nodes of the lower mediastinum are also 
removed. In the reconstruction phase, esophagojejunostomy is performed [2]. Anastomosis 
was mainly hand-sewn from 2001 until 2012 in our institution and changed towards a stapler 
anastomosis.  
 
Abdomino- thoracic esophagectomy. After the first experience with esophagectomy, the 
proximal and distal remnants after resection were brought out subcutaneously and connected 
by external plastic tubes, skin tubes, or flaps. In 1933, Ohsawa reported the use of the 
stomach for orthotopic reconstruction of the resected esophagus. This technique was used in 
18 patients in Japan 
19
. Ohsawa performed a combined left thoracoabdominal incision for 
carcinomata of the lower third of esophagus. 
 
Ivor Lewis described the right thoracoabdominal esophageal resection and reconstruction in 
1946. He compared his technique to the left- sided approach and reported improved access to 
the 2 upper thirds of esophagus through the right- sided approach, the exposure of the whole 
esophagus after ligation of the azygos vein and the protection of the contralateral pleural 
cavity covered by the descending thoracic aorta 
20
. The surgical procedure consists of a 
median laparotomy, where the stomach is mobilized for the preparation of the gastric tube. 
15 
 
 
The esophagus is then resected in the level of azygos vein through a right thoracotomy 
incision along the fifth intercostal space, and an intrathoracic esophagogastric anastomosis is 
performed. The anastomosis is performed with the circular stapler in end-to-side technique, 
the stapler is inserted over the open end of the gastric tube (―Krückstock‖). The stapled 
anastomosis was sometimes oversewn with single 4-0 PDS stitches in our department. 
 
The gastric conduits were routinely performed according to Kirschner/ Akiyama 
21
; in three 
patients (3/179, 1.7%) a fundus rotation gastroplasty was performed to achieve longer gastric 
tubes and better blood supply 
22
. In the conventional Kirschner- Akiyama gastric tube, the 
„neo- esophageal― blood supply relies mainly on the right gastroepiploic vessels. The 
rationale of fundus rotation gastroplasty is the preservation of most of the arterial arcade 
along the minor curvature of the stomach 
22
. In the experimental setting it has been 
demonstrated that the fundus rotation gastroplasty tube is longer and better perfused than the 
conventional gastric tube 
23, 24
. 
 
 
 
 
 
 
 
 
 
 
 
 
  
16 
 
 
 (A) 
 
 (B) 
 
  (C) 
17 
 
 
 
 
 
Figure 2. Ivor-Lewis abdomino- thoracic esophagectomy: In the abdominal part of the procedure, a D2 
lymphadenectomy is performed and a gastric tube is prepared. In the thoracic part, the esophagus is dissected in 
the level of azygos vein. An esophagogastric anastomosis is performed. Formation of the gastric tube (A). One 
part of the circular stapler is inserted into the gastric tube (B), the other part is passed up though the esophagus 
and through the staple line (C). The two parts are then connected (DST Series™ EEA™ 25 mm single use 
stapler, Covidien, New Haven, CT, USA) above the azygos vein (Copyright University Clinic of Saarland). 
 
 
Mc Kewon 3- field esophagectomy. The three- field esophagectomy was described by Mc 
Kewon in 1976 
25
. In this type of surgery, a right posterolateral thoracotomy is performed at 
first, the esophagus is mobilized from the hiatus to the apex of the right chest. The abdominal 
part is analogous to the Ivor Lewis procedure. In the cervical part of the procedure, the 
anterior border of the left sternocleidomastoid muscle (SCM) is incised. After dividing the 
subcutaneous tissue and the platysma, the SCM and the carotid artery are retracted laterally, 
the larynx and trachea are retracted medially. In this surgical step an injury of the left 
recurrent laryngeal nerve should be avoided. As a next step, the omohyoid muscle, the 
inferior thyroid artery and the middle thyroid vein are divided. The esophagus is then bluntly 
dissected, posteriorly to expose the prevertrebal fascia. After completion of the mobilization, 
the esophagus is dissected away from the trachea, then clamped and transected in the neck 
with a scalpel. The gastric tube is retrosternally mobilized to the neck and a two- layer,   
hand- sewn esophagogastrostomy is performed 
25
.  
 
The argument in favor of this more extensive surgical operation is, that lymph node 
metastasis in esophageal cancer occurs in early stages, involving in case of thoracic 
esophageal cancer the bilateral paratracheal lymph nodes, the paracardiac nodes, cervical 
18 
 
 
lymph nodes and lymph nodes along the left gastric artery. Akiyama et al. reported good 
postoperative results with the Mc Kewon 3- field esophagectomy 
26
.   
 
In patients with a history of previous gastrectomy, interposition of parts of the colon is 
necessary to reconstruct the gastrointestinal continuity, as described in the literature 
27
. The 
ascending and transverse colon were used as interposed grafts. A colonoscopy to exclude 
malignancy was preoperatively performed in these patients.  
 
All of the above mentioned surgical procedures were performed over a 14- year period in our 
department. 
 
Classification of abdominal lymphadenectomy. The Japanese research society for the study 
of gastric cancer published a manual in 1963, standardizing lymphadenectomy and pathologic 
evaluations for gastric cancer. These guidelines recognized 16 lymph node stations (JGCA: 
Japanese classification of gastric carcinoma-2nd Engl.ed.)
28
.  
 
16 nodal stations are characterized in relation to the localization and extent of the primary 
tumor (N0-N4). The extent of lymphadenectomy is classified accordingly to the level of 
lymph node stations (D1-D4). In D1 dissections, only the perigastric nodes directly attached 
along the minor and major curvature of the stomach are removed (stations 1-6, N1 level). An 
incomplete N1 dissection is refered to as D0 lymphadenectomy. In D2 dissections (N2 level), 
the lymph nodes along the left gastric artery (station 7), the common hepatic artery (station 8), 
the celiac trunk (station 9), the splenic hilus, and the splenic artery (stations 10 and 11) are 
additionally removed.  D3 dissections include the additional dissection of lymph nodes (LN) 
at stations 12, 13 and 14, along the hepatoduodenal ligament and the root of the mesenteric 
artery (N3 level). Finally, D4 resections include the LN stations 15 and 16 in the paraaortic 
and the paracolic region (N4 level).  It is thought that the incidence of LN metastasis to any of 
the above described lymph nodal stations is higher, if the primary tumor is localized nearby. 
For tumors in antrum, tumor infiltrating the right paracardiac lymph nodes are staged as N2, 
while tumor infiltrating the left paracardiac lymph nodes are staged as N3. For tumors of 
cardia,  the 5th and 6th lymph nodal stations belong to N2 level 
28
. 
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Summary of regional lymph nodes  
No. 1 Right paracardial lymph nodes (LN)  
No. 2 Left paracardial LN  
No. 3 LN along the minor curvature  
No. 4sa LN along the short gastric vessels  
No. 4sb LN along the left gastroepiploic vessels  
No. 4d LN along the right gastroepiploic vessels  
No. 5 Suprapyloric LN  
No. 6 Infrapyloric LN  
No. 7 LN along the left gastric artery  
No. 8a LN along the common hepatic artery (anterosuperior group)  
No. 8p LN along the common hepatic artery (posterior group)  
No. 9 LN around the celiac trunk  
No. 10 LN at the splenic hilus  
No. 11p LN along the proximal splenic artery  
No. 11d LN along the distal splenic artery  
No. 12a LN in the hepatoduodenal ligament (along the hepatic artery)  
No. 12b LN in the hepatoduodenal ligament (along the bile duct)  
No. 12p LN in the hepatoduodenal ligament (behind the portal vein)  
No. 13 LN on the posterior surface of the pancreatic head  
No. 14v LN along the superior mesenteric vein  
No. 14a LN along the superior mesenteric artery  
No. 15 LN along the middle colic vessels  
No. 16a1 LN in the aorta  
No. 16a2 LN around the abdominal aorta (from the upper margin of the celiac trunk to the  
lower margin of the left renal vein)  
No. 16b1 LN around the abdominal aorta (from the lower margin of the left renal vein to the  
upper margin of the inferior mesenteric artery)  
No. 16b2 LN around the abdominal aorta (from the upper margin of the inferior mesenteric  
artery to the aortic bifurcation)  
No. 17 LN on the anterior surface of the pancreatic head  
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Apart from standard D2 lymphadenectomy, the lymph nodes of the lower mediastinum were 
routinely resected during transhiatal esophagectomy in our institution. 
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1.4.2 Clavien- Dindo classification of surgical complications.  
Clavien et al. introduced a classification system for surgical complications using the example 
of cholecystectomy in 1992 
29, 30
. This system facilitates the assessment of the severity of 
postoperative complications. It is based on the required treatment, and due to its applicability, 
it was also used in other fields of surgery 
31
 to describe the severity of surgical complications. 
We used the Clavien- Dindo classification in our study to classify the severity of 
postoperative complications. 
 
Table 5. The Clavien- Dindo Classification of surgical complications 
30
 
 
Grades: Definition                                                          
I: Any deviation from the normal postoperative course without the need for pharmacological treatment 
or surgical, endoscopic and radiological intervention. Allowed therapeutic regimens are drugs like 
antiemetics, antipyretics, analgetics, diuretics and electrolytes and physiotherapy. This grade also 
includes wound infections opened at the bedside. 
 
II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications. 
Blood transfusions and total parenteral nutrition are also included. 
 
III: Requiring surgical, endoscopic or radiological intervention (IIIa: intervention under general 
anesthesia, IIIb: intervention under general anesthesia). 
 
IV: Life- threatening complication including CNS complications† requiring IC/ ICU- management (IVa: 
single organ dysfunction, including dialysis, IVb: multiorgan dysfunction). 
 
V: Death of patient. 
 
Suffix `d`: If the patients suffers from a complication at the time of discharge, the suffix `d` (for `disability`) is added to the 
respective grade of complication. This label indicates the need for a follow- up to fully evaluate the complication. 
 
† brain haemorrhage, ischemic stroke, subarachnoidal bleeding, but excluding transient ischemic attacks (TIA), IC: Intensive 
care, ICU: Intensive care unit. 
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1.4.3. Neoadjuvant therapy. The aim of neoadjuvant therapy regimens is to reduce local 
tumor infiltration, to prevent micrometastases, to increase the chance for R0 surgical 
resection, and consequently to increase long- term survival.  A combined, neoadjuvant 
radiochemotherapy was carried out for squamous- cell and neoadjuvant chemotherapy 
without radiation for adenocarcinoma of the esophagus, depending on tumor stage in our 
institution. The surgical resection followed at about 4 weeks after the end of the neoadjuvant 
therapy. Until 2012 we used the PLF- scheme, based on cisplatin, folic acid, 5- fluoruracil (5- 
FU) and simultaneous radiation [45 Gy (1,5 per day)] in cases of squamous- cell esophageal 
carcinoma. Since 11/2012, we have performed the neoadjuvant radiochemotherapy regimen 
as proposed by the dutch CROSS trial for both tumor entities (adenocarcinoma and 
squamous- cell carcinoma), consisting in weekly administration of carboplatin und paclitaxel 
for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions) followed by surgery. This 
scheme has been reported to be associated with low perioperative mortality (4%), high rates 
of pathological complete responders (up to 49% in squamous- cell esophageal carcinoma) and 
acceptable adverse-event rates 
32
. 
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1.5 Aims and scope. 
 
In the present study, we aimed to evaluate the results of the surgical therapy for esophageal 
cancer in our department in a time period from 2001- 2014. Primary end points were 
postoperative morbidity and overall survival after esophagectomy for esophageal cancer. 
Herein, we tried to identify risk factors for worse postoperative outcome and patients’ overall 
survival. 
 
In addition, special emphasis was given upon the impact of the type of anastomotic technique 
for gastrointestinal reconstruction (intrathoracic stapler versus hand- sewn esophagogastric 
anastomosis) after esophagectomy for cancer. A further focus was given on the impact of 
histological subtype (esophageal adenocarcinoma vs. squamous- cell carcinoma) on response 
to neoadjuvant therapy, disease free interval and overall survival.  
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2. Patients and methods: 
 
Patients who underwent surgery for esophageal cancer at the University Clinic of Saarland 
between 01.01.2001 and 31.12.2014 were included in this study. The perioperative data of the 
patients are routinely registered in a prospective electronic database: however, all records 
were reviewed again before performing the statistical analysis. The endoscopic and 
pathological findings were revised to follow the current TNM classification system and to 
ensure the correct classification of AEG tumors. The following data were included in the 
analysis: 
 
I. Patient characteristics:  
- Age at the time of surgery (in years).  
- Sex. 
- Comorbidities limited to coronary heart disease (CHD), chronic obstructive pulmonary 
disease (COPD), obesity (BMI exceeding 30 kg/m
2
). 
 
II. Tumor characteristics:  
-Tumor histology (squamous- cell carcinoma, adenocarcinoma, other histologies were 
excluded).  
-Tumor localization according to the current UICC classification system. 
- Preoperative neoadjuvant therapy (NAT). 
- T-/N-/M- stage pre- and    postoperatively. 
-―Response‖ to neoadjuvant therapy, divided in ―partial response‖ if a less aggressive tumor 
stage was diagnosed in the postoperative histopathologic specimen, in comparison to 
preoperative EUS staging, and ―complete ―response‖ to neoadjuvant therapy, if T0N0 was 
postoperatively diagnosed. 
 
III. Operative data:  
-Duration of the surgical procedure (in minutes). 
-Blood loss (in ml). 
-Number of dissected lymph nodes. 
-Surgical experience: chief surgeons, senior surgeons who performed more than 20 
esophagectomies, surgeons who performed less than 20 esophagectomies. 
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-Type of surgery: transhiatal esophagectomy with mediastinal anastomosis, transhiatal 
esophagectomy with cervical anastomosis, abdomino- thoracic esophageal resection with 
intrathoracic anastomosis, abdomino- thoracic esophageal resection with cervical 
anastomosis.  
 
-Type of anastomosis (hand-sewn, stapler anastomosis). 
 
IV. Postoperative data: 
-Minor postoperative complications Clavien- Dindo grade I -II. 
-Major postoperative complications Clavien- Dindo grade III –IV. 
-Reoperation. 
-Respiratory complications. 
-Anastomotic leakage, defined as disruption of the anastomosis that led to extravasation of 
intraluminal content.  
-30-, 60- and 90- days´ mortality. 
-Duration of the hospital stay (in days). 
-Anastomotic stricture and palsy of N. recurrens in the 6 months` follow- up. Anastomotic 
stricture was defined as dysphagia in the 6 months´ endoscopic control requiring intervention 
(endoscopic dilatation).   
-Tumorprogress and disease free interval (DFI). 
 
V. Overall survival data (OS): 
-Survival (in months). 
 
Perioperative management: During surgery, single- shot antibiotics ceftriaxon 2 g i.v. 
(clindamycin 600 mg i.v. in case of penicillin allergy) and metronidazol 500 mg i.v. were 
administrated. A nasogastric tube was positioned intraoperatively beneath the anastomosis 
and remained in situ for 5 days postoperatively, if not prematurely removed. The patient 
received parenteral feeding during these 5 days. If the anastomosis was patent in the 
postoperative radiographic control at the fifth postoperative day, the nasogastric tube was 
removed and enteral feeding with liquids was started. Postoperative chest X- rays were 
performed before and after removing the intraoperatively placed chest tubes, or whenever 
required during ICU stay.   
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Two easy- flow drainage tubes were intraoperatively placed into the abdomen (one in the 
hiatus esophagei, one under the liver, the gallbladder was routinely intraoperatively removed) 
and two intrapleural drains, if the thorax was intraoperatively opened (one basolateral, one 
cranial from the esophagogastric anastomosis). A third one was placed into the left pleural 
cavity, if left- sided pleura was opened intraoperatively. 
 
All patients were initially admitted to the intensive care unit (ICU), at least for one 
postoperative day. The laryngeal tubus was immediately removed, if possible. Peridural 
catheter was used for analgesia if not contraindicated, and continuous positive airway 
pressure (CPAP) mask therapy was initially performed to prevent pulmonal atelectasis. 
Depending on the clinical course, patients were transferred to the intermediate care ward for 
the next 2- 4 days and then to the peripheral surgical wards.  Parenteral feeding started at the 
first postoperative day to meet caloric requirements. Patients were postoperatively discussed 
in the tumorboard for the need of adjuvant therapy. The postoperative 6- months´ follow- up 
was routinely performed either by the primary care physician or in our hospital.   
 
Severity of postoperative morbidity: In order to assess the severity as well as the clinical 
impact of perioperative morbidity, the Clavien- Dindo classification was used 
30
. The overall 
postoperative morbidity during patient’s first hospital stay was classified into minor (Clavien- 
Dindo grade I- II) or major complications (Clavien- Dindo grade III- IV). The group of minor 
postoperative morbidity consisted of complications treated conservatively. The group of 
major postoperative morbidity consisted of complications requiring surgical, endoscopic or 
radiological intervention (Clavien- Dindo grade IV), life- threatening complications requiring 
ICU management (grade IV) or lethal complications (grade V). All of the patients received 
parenteral feeding for 5 days. For this reason, the administration of parenteral feeding was not 
assessed as a Clavien- Dindo grade I complication. N. recurrens palsy was classified as 
Clavien- Dindo grade IIId complication. Mortality during the first hospital stay was stratified, 
and 30-, 60- and 90- days´ mortality were separately assessed. 
   
Tumor management: Endosonography (EUS) was preoperatively performed as well as 6 
months postoperatively during routine follow- up. In the preoperative work- up, a computed 
tomography (CT) was performed to detect any organ metastases. Neoadjuvant chemotherapy 
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combined with radiation in case of SCC was preoperatively performed, if uT3 or N+ or 
both/higher tumor stage was diagnosed in preoperative endosonography  
33
. The surgical 
resection followed 4- 6 weeks after the end of the neoadjuvant therapy. Until 2012, the PLF- 
scheme based on cisplatin, folic acid, 5- FU and simultaneous radiation [45 Gy (1,5 per day)] 
in cases of squamous- cell esophageal carcinoma was used. Since 2012, neoadjuvant 
chemoradiation regimen as proposed by the dutch CROSS trial, consisting in weekly 
administration of carboplatin und paclitaxel for 5 weeks and concurrent radiotherapy (41.4 Gy 
in 23 fractions) followed by surgery was performed.  
 
Statistical analysis: The χ² test (Fisher's exact test) and the binary logistic regression in case 
of categorical variables, as well as Mann-Whitney U test and Kruskal-Wallis H test in case of 
non- parametric, not normally distributed continuous variables were performed. The 
distribution of continuous variables was tested with the Kolmogorov- Smirnov test. Statistical 
significance was set at p≤ 0.05. Survival data were recorded partially contacting the Cancer 
Registry of Saarland and partially contacting the house doctors. Log rank test and Cox- 
regression were performed for survival analysis. Statistical analysis was conducted using IBM 
SPSS Statistics V22.0. 
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3. Results: 
 
3.1. Descriptive Analysis:   
 
320 patients with esophageal cancer were treated in the University Clinic of Saarland 
from 01.01.2001 until 31.12.2014. Overall, the men/ women ratio was 268:52 
(83.8%:16.2%), and the median age of patients at the time of operation was 63 years 
(min. 28 years, max. 88 years). Regardless of the tumor stage or its localisation, 
median overall survival was 17 months (0- 146.5 months). The 1-, 3- and 5 –year 
survival was 65.2%, 41.7% and 30.7%, the 30- day, 60- day and 90- day mortality 
rates were 5.9% (19/320), 9.4% (30/320) and 12.8% (41/320), respectively. 
 
3.1.1. Patient characteristics. Patient characteristics are shown in table 6. 37.8% of 
the patients had a squamous- cell esophageal cancer (SCC), while 62.2% (199/320) 
suffered from adenocarcinoma of the esophagus. In 44.6% of patients with a SCC 
(54/121) and 62.8% with an esophageal adenocarcinoma (125/199) an abdomino- 
thoracic esophageal resection with intrathoracic anastomosis was performed (TAE 
intrathoracic group). 25.6% (82/320) patients had a chronic obstructive pulmonary 
disease (COPD) at the time of surgery, 21.3% (68/320) a history of coronary heart 
disease (CHD) and 20.9% (67/320) were obese. Overall, 51.9% of the patients 
(166/320) received neoadjuvant therapy.   
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Table 6. Esophagectomies for esophageal cancer (n= 320). Patient characteristics 
  Parameters         THE                 THE                TAE                TAE           Total        P            
                       intraabdominal     cervical         intrathoracic     cervical 
                            59, 18.4%             30, 9.4%             179, 55.9%            52, 16.2%        320, 100% 
 
Age in years               67 (38)                 70 (37)                 61 (54)                 61 (39)             63 (60)      0.149 
(median, range)     
                  
Men/women ratio         45/14                 25/5                    156/23                 42/10              268/52            0.23 
(n, %)                       76.3%/27%       83.3%/16.7%      87.1%/12.9%      80.8%/19.2%   83.8%/16.2% 
                     
Adenocarcinoma        56 (94.5%)      12 (40%)           125 (69.8%)          6 (11.5%)        199 (62.2%)    <0.001*** 
of esophagus (n, %)                        
        
Squamous- cell            3 (5.5%)           18 (60%)          54 (30.2%)            46 (88.5%)    121 (37.8%)   <0.001*** 
carcinoma of                          
esophagus (n, %)                         
     
COPD (n, %)              11 (18.7%)        10 (33.3%)            47 (26.3%)        14 (26.9%)      82 (25.6%)        0.47 
                                                
Coronary Heart           15 (25.4%)         12 (40%)              33 (18.4%)         8 (15.4%)       68 (21.3%)      0.032* 
Disease (n, %)                          
                    
Obesity (n, %)             18 (30.5%)           6 (20%)              34 (19%)           9 (17.3%)        67 (20.9%)       0.251 
                                               
Neoadjuvant                29 (49.2%)        13 (43.3%)          100 (55.9%)        24 (46.2%)     166 (51.9%)      0.529 
therapy (n, %)                                               
 
TAE cervical: abdomino- thoracic esophageal resection with cervical anastomosis, TAE intrathoracic: 
abdomino- thoracic esophageal resection with intrathoracic anastomosis, THE cervical: transhiatal 
esophagectomy with cervical anastomosis, THE intraabdominal: transhiatal esophagectomy with 
intraabdominal anastomosis, SCC: squamous- cell esophageal carcinoma, AEG: adenocarcinoma of the 
gastroesophageal junction. 
 
* p <0.05, *** p< 0.001 
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3.1.2. Tumor characteristics. 
 
Table 7. Esophagectomies for esophageal cancer (n= 320).  
Histology and tumor localization 
                                                                                n                                                     % 
 
SCC                                                                              121                                                       37.8      
SCC upper 1/3                                                              12                                                         3.7 
SCC middle 1/3                                                             57                                                        17.8 
SCC lower 1/3                                                               52                                                        16.3 
AEG                                                                              199                                                       62.2         
AEG I                                                                            106                                                       33.1 
AEG II                                                                           56                                                        17.5  
AEG III                                                                          37                                                        11.6     
Total                                                                              320                                                       100                                                
 
121 patients (37.8%) had a squamous- cell esophageal carcinoma (SCC). In 12 patients the 
SCC was located in the upper 1/3 of the esophagus (3.7%), in 57 patients in the middle 1/3 
(17.8%) and in 52 in the lower 1/3 (16.3%). 199 patients (62.2 %) had an esophageal 
adenocarcinoma; in 106 adenocarcinoma of the esophago -gastric junction Type I (AEG I) 
according the Siewert classification (33.1%), in 56 AEG of Type II (17.5%) and in 37 AEG of 
Type III (11.6%), as given in table 7.  
 
The median value of dissected lymph nodes was 17 (min= 2, max= 65).  
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Table 8. Esophagectomies for esophageal cancer (n= 320). 
UICC tumor stage 
Stage                                  n                                    % 
0                                        33                                 10.3 
I                                         53                                16.6 
II                                       97                                 30.3 
III                                     113                                35.3 
IV                                      24                                  7.5 
Total                                 320                                100 
 
 
Table 8 shows tumor staging data of the patients. The majority of patients experienced a 
tumor stage III (35.3%, 113/320), followed by stage II (30.3 %, 97/320), stage I (16.6 %, 
53/320) and stage IV (7.5 %, 24/320).  Interestingly, 10.3% of patients (33/320) experienced 
stage 0 in the postoperative pathological assessment.  
 
3.1.3. Operative data and postoperative outcome. 
 
In more than half of our patients, abdomino- thoracic esophageal resection (TAE) with 
intrathoracic anastomosis was performed (179 patients, 55.9%), transhiatal esophagectomy 
(THE) with intraabdominal anastomosis in 59 patients (18.4 %), abdomino- thoracic 
esophageal resection (TAE) with cervical anastomosis in 52 patients (16.3 %) and transhiatal 
esophagectomy (THE) with cervical anastomosis in 30 patients (9.4 %), as given in table 6.  
 
In 222 patients (69.4 %) hand- sewn, double- row, end- to- end anastomosis, and in 98 
patients (30.6 %) a stapled, end- to- side anastomosis was performed (table 9). Table 10 
depicts the type of surgery performed for each histological type and localization of the tumor.  
 
106 patients (33.1 %) had an esophageal adenocarcinoma type I (AEG I). In these, TAE with 
intrathoracic anastomosis was performed in 79 patients (24.7%), THE with cervical 
anastomosis in 11 patients (3.4%), THE with intraabdominal anastomosis in 11 patients 
(3.4%), and TAE with cervical anastomosis in 5 patients (1.6%), respectively (table 10).  
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Table 9. Esophagectomies for esophageal cancer (n= 320).  
Surgical procedure and type of anastomosis  
                                Hand- sewn, double- row      Stapled, end-to-side               Total  
                                      end-to-end                         (circular stapler) 
                                             n (%)                                   n (%)                             n (%) 
TAE cervical                  52 (16.2%)                                       0 (0%)                             52 (16%) 
TAE intrathoracic         129 (40.3%)                                   50 (15.6%)                       179 (55.9%) 
THE cervical                    30 (9.5%)                                        0 (0%)                            30 (9.5%) 
THE intraabdominal        11 (3.4%)                                     48 (15%)                          59 (18.4%) 
Total                               222 (69.4%)                                  98 (30.6%)                       320 (100%) 
 
TAE cervical: abdomino- thoracic esophageal resection with cervical anastomosis, TAE intrathoracic: 
abdomino- thoracic esophageal resection with intrathoracic anastomosis, THE cervical: transhiatal 
esophagectomy with cervical anastomosis, THE intraabdominal: transhiatal esophagectomy with 
intraabdominal anastomosis. 
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Table 10. Esophagectomies for esophageal cancer (n= 320).  
Surgical procedure, histology and localization of the tumor 
                                     SCC      SCC       SCC            AEG         AEG        AEG       Total  
                                   upper     middle     lower            I                II            III 
                                    1/3         1/3           1/3 
                                   n (%)     n (%)         n (%)         n (%)        n (%)       n (%)      
TAE cervical                5 (1.6%)   33 (10.3%)   8 (2.5%)        5 (1.6%)       1 (0.3%)     0 (0%)         52 (16.3%) 
TAE intrathoracic        0(0%)       19 (5.9%)   35 (10.9%)    79 (24.7%)   36 (11.3%)   10 (3.1%)   179 (55.9%) 
THE cervical               7 (2.2%)    4 (1.3%)       7 (2.2%)       11(3.4%)      1 (0.3%)      0 (0%)        30 (9.4%) 
THE intraabdominal    0 (0%)       1 (0.3%)       2 (0.6%)       11 (3.4%)    18 (5.6%)    27 (8.4%)    59 (18.4%) 
Total                          12 (3.8%)    57 (17.8%)   52 (16.2%)   106 (33.1%) 56 (17.5%) 37 (11.6%) 320, 100 % 
 
TAE cervical: abdomino- thoracic esophageal resection with cervical anastomosis, TAE intrathoracic: 
abdomino- thoracic esophageal resection with intrathoracic anastomosis, THE cervical: transhiatal 
esophagectomy with cervical anastomosis, THE intraabdominal: transhiatal esophagectomy with 
intraabdominal anastomosis, SCC: squamous- cell esophageal carcinoma, AEG: adenocarcinoma of the 
gastroesophageal junction. 
 
 
 
 
Table 11. Esophagectomies for esophageal cancer (n= 320).  
Surgical procedure and type of gastric tube 
                                Conventional gastric tube        Fundus rotation                     Total  
                                      Kirschner/ Akiyama             gastroplasty 
                                               n (%)                                  n (%)                              n (%) 
TAE cervical                         27 (8.4%)                                25 (7.8%)                         52 (16.2%) 
TAE intrathoracic                 176 (55%)                                  3 (0.9%)                        179 (55.9%) 
THE cervical                        14 (4.5%)                                  16 (5%)                           30 (9.5%) 
THE intraabdominal            59 (18.4%)                                  0 (0%)                           59 (18.4%) 
Total                                    276 (86.2%)                             44 (13.8%)                      320 (100%) 
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The majority of gastric conduits were conventionally performed (86.2%), whereas in 44 
patients (44/320, 13.8%) a fundus rotation gastroplasty was performed in order to achieve a 
longer gastric tube with an improved vascular perfusion. As shown in table 11, a fundus 
rotation gastroplasty was performed in case of cervical anastomosis and only 3 times in case 
of an intrathoracic anastomosis (3/320, 0.9%).   
 
The morbidity and mortality during patients’ first hospital stay is thoroughly described in the 
tables 12- 14. A total of 167 patients (52.2%) suffered from at least one postoperative 
complication. 47 patients (14.7 %) suffered from anastomotic leak, whereas 96 patients (30%) 
suffered from a respiratory complication (table 12). The 30- day, 60- day and 90- day 
mortality rates were 5.9% (19/320), 9.4% (30/320), and 12.8% (41/320) respectively. 
 
There was observed significant difference among the different types of surgery concerning 
duration of surgical procedure, and rates of postoperative complications Clavien- Dindo III- 
IV, respiratory complications, reoperation, palsy of N. recurrens, and 90- day mortality 
(p=0.01, p< 0.001, p<0.001, p=0.013, p<0.001, and p<0.001 respectively, x² exact test), as 
shown in table 12. More specially, the postoperative morbidity and 90- day mortality after 
cervical anastomosis, either in the frame of TAE or THE, was significantly higher in 
comparison to other types of surgery. 
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Table 12. Esophagectomies for esophageal cancer (n= 320). Operative data and postoperative outcome 
among different types of surgery 
Parameters                       THE                 THE                TAE                  TAE              Total           P  
                                 intraabdominal       cervical         intrathoracic     cervical                                                 
                                    59 (18.4%)           30 (9.4%)          179 (55.9%)        52 (16.2%)      320 (100%) 
 
Duration of surgical          201 [77, 354]       242.5 [125, 548]     269 [128, 532]      333 [168, 675]     257 [77, 675]      0.01**             
 procedure  
median [min., max.]   
 
Blood loss in ml              200 [20, 1500]        500 [50, 6000]       300 [5, 4000]       350 [100, 1200]    300 [5, 6000]       0.797 
median [min., max.]   
 
Number of dissected              19 [6, 65]           14 [3, 49]                 17 [3, 62]              14 [2, 49]         17 [2, 65]             0.388 
lymph nodes                                        
median [min., max.] 
          
Minor postoperative                4 (6.8%)             3 (10%)                 23 (12.8%)            10 (19.2%)      40 (12.5%)            0.25 
complications Clavien- Dindo 
Grade I-II  
n (%)    
 
Major postoperative              21 (35.6%)         9 (30%)                  29 (16.2%)             27 (51.9%)    86 (26.9%)   p<0.001 ***    
complications Clavien- Dindo 
Grade III-IV  
n (%)    
Respiratory  
complications n (%)               9 (15.3%)          16 (53.3%)               47 (26.3%)             24 (46.1%)       96 (30%)    p<0.001 ***    
Reoperation n (%)               18 (30.6%)          16 (53.3%)               47 (26.3%)             21 (40.4%)      102 (31.9%)      0.013* 
Anastomotic leak n (%)         9 (15.3%)            9 (30%)                  22 (12.3%)              7 (13.5%)        47 (14.7%)        0.11 
Anastomotic stricture n (%)    3 (5%)               3 (10%)                  20 (11.2%)              4 (7.7%)          30 (9.4%)          0.543 
Palsy of  N. recurrens n (%)    0 (0%)              7 (23.3%)                  3 (1.7%)              14 (26.9%)        24 (7.5%)    p<0.001*** 
30- day  mortality n (%)          2 (3.4%)           5 (16.7%)                  6 (3.4%)               6 (11.5%)         19 (5.9%)          0.103 
60- day  mortality n (%)          4 (6.8%)           8 (26.7%)                 11 (6.1%)              7 (13.5%)         30 (9.4%)        0.007 **    
90- day  mortality n (%)          4 (6.8%)          11 (36.7%)               18 (10.1%)             8 (15.4%)         41 (12.8%)   p<0.001***      
Hospital stay (days)              19 [8, 118]         29 [8, 127]                20 [9, 198]           25 [10, 114]       22 [8, 198]        0.164 
median [min., max.]                                                                                                                    
*  p <0.05, **  p<0.01, ***  p< 0.001 
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3.1.4. Postoperative complications according to Clavien- Dindo. 
 
To assess the severity of postoperative morbidity, we recorded the postoperative 
complications according to Clavien- Dindo classification. 40 patients (12.5%) suffered from a 
minor postoperative complication (Clavien- Dindo grade I- II), whereas 86 patients (26.9%) 
experienced a major postoperative complication (Clavien- Dindo grade III- IV), thus requiring 
surgical, endoscopic or radiological intervention or readmission in the Intensive Care Unit 
(ICU). A total of 41 patients (12.8%) suffered from a lethal postoperative complication 
(Clavien- Dindo grade V), as shown in table 13.   
 
Table 13. Esophagectomies for esophageal cancer (n= 320). 
Classification of postoperative complications after Clavien- Dindo 
Grade                                 n                                    % 
No complication              153                                 47.8 
I                                         19                                   5.9 
II                                        21                                   6.6 
III                                      60                                  18.8 
IV                                      26                                  8.1 
V                                       41                                  12.8 
Total                                 320                                 100 
 
Patients with minor postoperative complication (grade I- II according to Clavien- Dindo) 
suffered mainly from respiratory complication (24/40 patients, 60%). On the contrary, 
surgical complications (anastomotic leak, necrosis of the gastric tube) led predominantly to 
major and lethal postoperative morbidity (Clavien- Dindo grade III- V). In particular, 23 out 
of 86 patients with Clavien- Dindo III- IV complications suffered from anastomotic leak 
(26.7%), whereas 24 patients (27.9%) suffered from palsy of N. recurrens. Surgical 
complications (anastomotic leak in 21 patients, necrosis of gastric tube in 9 patients) were 
predominantly responsible for lethal complications Clavien- Dindo grade V, as shown in table 
14.  
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Table 14. Esophagectomies for esophageal cancer (n= 320). 
Postoperative morbidity among different types of surgery 
                                               THE              THE           TAE                 TAE             Total  
                                      intraabdominal   cervical    intrathoracic    cervical 
                                         59 (18.4%)     30 (9.4%)   179 (55.9%)   52 (16.2%)    320 (100%) 
Minor postoperative 
complications  
Clavien- Dindo                     4 (6.8%)          3 (10%)       23 (12.8%)      10 (19.2%)         40 (12.5%) 
Grade I&II   n (%) 
Anastomotic leak treated 
conservatively                        1 (1.7%)          0 (0%)           0 (0%)             2 (3.8%)             3 (0.9%) 
Esophageal fistula                  0 (0%)            1 (3.3%)         0 (0%)             0 (0%)                1 (0.3%) 
Chyle leak treated 
conservatively                         0 (0%)            1 (3.3%)         4 (2.2%)          2 (3.8%)             7 (2.2%) 
Wound infection                     0 (0%)             0 (0%)           3 (1.7%)          2 (3.8%)             5 (1.6%)   
Pneumonia                             1 (1.7%)           1 (3.3%)        7 (3.9%)          0 (0%)                9 (2.8%) 
Pleura effusion treated             
with diuretics                         2 (3.4%)           0 (0%)           8 (4.5%)          2 (3.8%)            12 (3.8%) 
Pneuothorax with no need  
for extra chest tube                 0 (0%)            0 (0%)            1 (0.6%)           2 (3.8%)            3 (0.9%)  
Major postoperative 
complications  
Clavien- Dindo  
Grade III&IV n (%)                 21 (35.6%)    9 (30%)      29 (16.2%)      27 (51.9%)       86 (26.9%)  
 
Anastomotic leak                        6 (10.2%)     3 (10%)         7 (3.9%)          0 (0%)            16 (5%)   
Anastomotic leak+ 
mediastinitis                                 0 (0%)        0 (0%)           5 (2.8%)           0 (0%)            5 (1.6%)   
Anastomotic leak+ 
respiratory insufficiency             0 (0%)        0 (0%)           1 (0.6%)          0 (0%)             1 (0.3%)   
Anastomotic leak+ 
hiatal hernia                                0 (0%)        0 (0%)           1 (0.6%)          0 (0%)             1 (0.3%)      
Necrosis of the gastric tube        0 (0%)        0 (0%)           4 (2.2%)          0 (0%)             4 (1.3%)    
Peforated ulcus of the 
38 
 
 
gastric tube                                 1 (1.7%)        0 (0%)           1 (0.6%)          0 (0%)           2 (0.7%) 
Necrosis of the colon  
interposition                               0 (0%)           0 (0%)              0 (0%)           1 (1.9%)         1 (0.3%)  
Hemorrhage                              4 (6.8%)        1 (3.3%)            0 (0%)           1 (1.9%)         6 (1.9%)   
Insufficiency of the  
duodenal stump                         1 (1.7%)         0 (0%)             0 (%)             0 (0%)            1 (0.3%) 
Pancreatic fistula                       1 (1.7%)         0 (0%)             0 (%)             0 (0%)            1 (0.3%) 
Biliary leak                                0 (0%)            0 (0%)          1 (0.6%)           0 (0%)            1 (0.3%) 
Intra-abdominal abscess            1 (1.7%)         0 (0%)             0 (%)             0 (0%)            1 (0.3%) 
Hiatal hernia                              1 (1.7%)         0 (0%)          1 (0.3%)           0 (0%)            2 (0.6%) 
Wound dehiscence                      0 (0%)         1 (3.3%)         7 (3.9%)           0 (0%)           8 (2.5%) 
Adhesion ileus                           0 (0%)            0 (0%)          1 (1.9%)           0 (0%)            1 (0.3%) 
Chyle leak with need for 
Reoperation                                0 (0%)           0 (0%)           6 (3.4%)           5 (9.6%)         11 (3.4%) 
Iatrogene perforation of 
small intestine                            0 (0%)          1 (3.3%)          0 (0%)            0 (0%)              1 (0.3%) 
Palsy of N. recurrens                  0 (0%)          7 (23.3%)       3 (1.7%)        14 (26.9%)        24 (7.5%)  
Pneumonia resulting in 
respiratory insufficiency           1 (1.7%)         2 (6.7%)         7 (3.9%)         5 (9.6%)          15 (4.7%)  
Pleura effusion with need  
for draining tube                       1 (1.7%)          1 (3.3%)        7 (3.9%)           0 (0%)             9 (2.8%) 
Pneumothorax with need  
for draining tube                       2 (3.4%)           3 (10%)          0 (0%)             0 (0%)             5 (1.6%) 
Pulmonary embolism               1 (1.7%)            1 (3.3%)        1 (0.6%)           3 (5.8%)          6 (1.9%) 
Sepsis after aspiration               0 (0%)              1 (3.3%)        0 (0%)              3 (5.8%)          4 (1.3%) 
Pericardial tamponade              0 (0%)               0 (0%)          0 (0%)             1 (1.9%)           1 (0.3%) 
 
Lethal postoperative 
complications  
Clavien- Dindo  
Grade V, n (%)                      4 (6.8%)           11 (36.7%)     18 (10.1%)       8 (15.4%)      41 (12.8%) 
Anastomotic leak                     0 (0%)              2 (6.7%)         3 (1.7%)          3 (5.8%)         8 (2.5%) 
Anastomotic leak+ 
fistula                                      0 (0%)                0 (0%)           3 (1.7%)           1 (1.9%)        4 (1.2%) 
Anastomotic leak+ 
mediastinitis                            2 (3.4%)            4 (13.3%)       2 (1.1%)           1 (1.9%)        9 (2.8%)  
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Necrosis of the gastric 
tube                                         2 (3.4%)            5 (16.7%)        1 (0.6%)           1 (1.9%)       9 (2.8%) 
Hemorrhage from 
gastric tube                              0 (0%)              0 (0%)             2 (1.2%)            0 (0%)          2 (0.6%) 
Sepsis after aspiration             0 (0%)              1 (3.3%)          3 (1.7%)           1 (1.9%)        5 (1.5%) 
Massive pulmonary 
embolism                                0 (0%)              0 (0%)             3 (1.7%)            0 (0%)          3 (0.9%) 
Pericardial tamponade            0 (0%)              0 (0%)             1 (0.6%)            0 (0%)          1 (0.3%) 
  
 
3.1.5. Complications at 6 months´ follow- up: 24 out of 320 patients (7.5%) suffered from 
N. recurrens palsy at the time of discharge (Clavien- Dindo IIId complications); 21/320 of 
patients (6.6%) were subjected to cervical anastomosis. Furthermore, 30 patients (9.4%) 
suffered from anastomotic stricture, of which 20 patients (6.3%) had undergone abdomino-
thoracic esophagectomy with intrathoracic anastomosis. 
 
 
3.2. Impact of anastomotic technique (intrathoracic stapler versus hand- sewn 
esophagogastric anastomosis) on postoperative outcome after abdomino-thoracic 
esophagectomy for cancer. 
 
We investigated in particular, whether the type of anastomosis (hand- sewn, or stapler) 
influenced the postoperative outcome. For this purpose, we analyzed 179 patients, who 
underwent abdomino-thoracic resection with intrathoracic anastomosis. Three patients with a 
fundus rotation gastroplasty were excluded, and the remaining 176 patients were divided into 
two groups: group 1 hand- sewn, double row, end-to-end anastomosis (with 4-0 PDS and 5-0 
PDS stitches), group 2 one row end-to-side, stapler. Both groups were compared in terms of 
morbidity and mortality. Demographic, operative and postoperative data were recorded for 
both groups.  
 
3.2.1. Patient characteristics, operative data and postoperative outcome. Hand- sewn 
anastomosis was carried out in 126 patients (group 1) and stapler anastomosis in 50 patients 
(group 2). Patient characteristics were similar in both groups (table 15): Median age of 
patients at the time of surgery was 61 years [34- 88], with more men than female patients 
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(153/ 23). 52 patients (29.5%) suffered from squamous- cell esophageal cancer (SCC), and 
124 patients (70.5%) from esophageal adenocarcinoma. 45 patients (25.6%) had chronic 
obstructive pulmonary disease (COPD) at the time of surgery, 33 patients (18.9%) coronary 
heart disease (CHD) and 34 patients (19.3%) were obese. The preoperative rates of COPD 
(p=0.13), CHD (p=0.20) and obesity (p=0.42) were not significantly different among both 
groups. A total of 93 patients (52.8%) were admitted to neoadjuvant therapy due to 
preoperative staging (group 1: 47.6% vs. group 2: 66%, p=0.11). 
  
Table 15. Esophagectomies for esophageal cancer (n= 176). Patient characteristics 
    Characteristic                              Hand-sewn                Stapler              Total         P value 
                                                               126                        50                      176  
Age in years, median [min, max.]          62 [42,88]             61 [34,84]               61 [34,88]                0.34 
Men/women ratio n (%)                  111/15 (88%/12%)   42/8 (84%/16%)  153/23 (86.9%/13.1%)   0.23  
Adenocarcinoma of esophagus n (%)    86 (68.3%)               38 (76%)             124 (70.5%)              0.21   
Squamous- cell carcinoma of                 40 (31.7%)               12 (24%)              52 (29.5%)              0.21         
esophagus n (%)     
COPD n (%)                                          35 (27.8%)                 10 (20%)              45 (25.6%)            0.13   
Coronary Heart Disease n (%)               26 (20.6%)                  7 (14%)              33 (18.9%)            0.20   
Obesity n (%)                                         24 (19%)                    10 (20%)             34 (19.3%)            0.42 
Neoadjuvant therapy n (%)                    60 (47.6%)                 33 (66%)              93 (52.8%)           0.11               
 
  
Median duration of surgery was 269 min. [128- 532 min.], whereas the median intraoperative 
blood loss was 300 ml [5- 4000 ml], as shown in table 16. The median number of dissected 
lymph nodes was 17 [3- 62].  
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Table 16. Esophagectomies for esophageal cancer (n=176): 
Operative data and postoperative outcome 
 Parameters                                 Hand- sewn            Stapler                Total               P value 
                                                               126                       50                        176 
Duration of surgical procedure         280 [128, 532]      261 [160, 376]        269 [128, 532]        0.49  
median [min, max]  
Blood loss in ml  
median [min, max]                           300 [50, 4000]       200 [5, 1500]          300 [5, 4000]          0.12    
Number of dissected                             17 [3, 62]              17 [6,34]              17 [3, 62]               0.59 
lymph nodes (median, [min, max]) 
Minor postoperative complications       13 (10.3%)           10 (20%)              23 (13%)               0.2  
Clavien- Dindo Grade I-II, n (%)   
 Major postoperative complications       25 (19.8%)             4 (8%)             29 (16.5%)              0.12 
Clavien- Dindo Grade III-IV, n (%) 
 Reoperation, n (%)                               43 (34.1%)              4 (8%)                47 (26.7%)          0.001***   
 Respiratory complications, n (%)         35 (27.8%)             12 (24%)           47 (26.3%)             0.36 
 Anastomotic leak, n (%)                     18 (14.3%)                 4 (8%)             22 (12.5%)              0.22 
Anastomotic stricture, n (%)                17 (13.5%)                  3 (6%)             20 (11.4%)             0.1 
30- day mortality, n (%)                        6 (4.8%)                   0 (0%)                6 (4.8%)               0.13 
60- day mortality, n (%)                       12 (9.6%)                   1 (2%)              13 (7.4%)              0.08  
90- day mortality, n (%)                       17 (13.5%)                 1 (2%)             18 (10.2%)             0.02 * 
Hospital stay in days                             21 [9, 198]              18 [12, 114]           20 [9, 198]           0.26 
median [min, max]  
*  p <0.05, **  p<0.01, *** p< 0.001 
 
 
23 patients (13%) suffered from minor postoperative complication (Clavien- Dindo Grade I-
II), whereas 29 patients (16.5%) suffered from major postoperative complication (Clavien-
Dindo Grade III- IV). 18 patients (10.2%) suffered from lethal postoperative complication 
(Clavien- Dindo Grade V) within 90 days after surgery.  
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Minor surgical complications included wound infection and chyle leak treated conservatively, 
while minor cardiopulmonary complications included pleura effusion treated with diuretics, 
pneumothorax with no need for draining tube, pneumonia and atrial fibrillation. The minor 
postoperative morbidity did not differ significantly among both groups (p=0.2). On the other 
hand, major surgical complications included anastomotic leak, necrosis of gastric tube, hiatal 
hernia, wound dehiscence, bile leak and chyle leak with need for reoperation. Surgical 
complications (anastomotic leak, necrosis of the gastric conduit) led predominantly to major 
and lethal postoperative morbidity (Clavien- Dindo Grade III- V).  
 
47 patients (26.7%) were reoperated during first hospital stay. The rate of reoperations 
differed substantially between both groups (group 1: 34.1% vs. group 2: 8%), p= 0.001). The 
incidence of anastomotic leak was 12.5% (22/176) and did not differ significantly among both 
groups (group 1: 14.3% vs. group 2: 8%, p= 0.22). The median hospital stay was 20 days [9, 
198] and did not significantly differ among both groups (p=0.26). The rate of anastomotic 
stricture in the 6 months´ follow-up was also similar among both groups (group 1: 13.5% vs. 
group 2: 6%, p= 0.1).   30-, 60- and 90- day mortality was 4.8% (n=6), 7.4% (n=13), and 
10.2% (n=18) respectively. The 90- day mortality was significantly lower in group 2 (group 
1: 13.5% vs. group 2: 2%, p= 0.02). The rate of reoperation, and consequently the 90- day 
mortality differed significantly among both groups. 
 
Management of anastomotic leak: In the stapler anastomosis group, anastomotic leaks were 
treated with endoscopic stent insertion: 4/ 50 patients after stapler anastomosis suffered from 
anastomotic leak, of whom only one was reoperated. On the contrary, in the hand- sewn 
anastomosis group, anastomotic leaks were predominantly treated with reoperation: 18 
patients after hand- sewn anastomosis suffered from anastomotic leak, of whom 14 were 
reoperated. Consequently, 90 days´ mortality (Clavien- Dindo grade V complications) and 
overall survival was statistically significantly different among both groups of patients.  
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3.2.2. Risk factors for major and lethal postoperative complications (Clavien- Dindo 
grade III- V) after abdomino- thoracic esophageal resection: Type of anastomosis and 
duration of surgery significantly influenced the incidence of major and lethal postoperative 
complications (Clavien- Dindo grade III- V) in the multivariate analysis (binary logistic 
regression, table 17). 
 
Table 17. Univariate and multivariate analysis of predictors of major postoperative 
complications (Clavien- Dindo III- IV) after resection for esophageal cancer 
                                               Univariate analysis                       Multivariate analysis 
Parameter                              OR (CI 95%)            P value       OR (CI 95%)          P value 
Age                                          1.022 (0.998-1.057)         0.200  
Sex                                           1.745 (0.703-4.331)         0.230 
CHD                                         1.847 (0.838-4.071)         0.130  
COPD                                       1.633 (0.802-3.327)         0.180      
Obesity                                      1.057 (0.465-2.403)        0.900   
Neoadjuvant therapy                 0.984 (0.486-1.993)        0.964  
Duration of surgery                   0.992 (0.987-0.997)      0.003**   0.991 (0.986-0.997)      0.002 ** 
Type of anastomosis                 3.296 (1.369-7.937)       0.008**   3.666 (1.499-8.963)      0.004 ** 
(hand-sewn vs. stapler) 
Intraoperative blood loss           1.000 (0.999-1.001)           0.68  
** p<0.01 
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3.2.3. Risk factors for anastomotic leak after abdomino -thoracic esophageal resection. 
Obesity, neoadjuvant therapy and anastomotic method did not significantly influence the 
incidence of anastomotic leak in the univariate analysis (table 18).  
 
 
Table 18. Risk factors for anastomotic leak after abdomino- thoracic resection for 
esophageal cancer 
                                                                                 Univariate analysis                         
Parameter                                         OR (CI 95%)                         P value         
Age                                                              0.984 (0.940-1.031)                          0.506 
Obesity                                                         1.390 (0.47-4.101)                           0.551  
 Neoadjuvant therapy                                    2.250 (0.775-6.534)                        0.136 
Type of anastomosis                                     1.746 (0.557-5.469)                          0.34 
(hand-sewn vs. stapler) 
 
 
 
3.2.4. Survival. Overall median patient survival was 18 months [0, 121]. In group 1 median 
survival was 22 months [0, 119], whereas in group 2, median survival was 16 months [1, 
121]. Patients subjected to hand- sewn anastomosis experienced worse overall survival, as 
well as patients with advanced UICC tumor stage (p= 0.001, and p=0.002 respectively, log 
rank test), as shown in table 19 and figure 3.  
  
In the multivariate analysis, type of anastomosis and advanced UICC tumor stage were 
independent factors, that significantly influenced overall survival (table 20, figure 4). 
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Table 19. Risk factors for worse overall survival after abdomino- thoracic resection 
for esophageal cancer -univariate analysis 
                                                              Log rank for                       Cox regression for 
                                                    categorical parameters              continuous parameters         
Parameter                                    P value              x ²                OR (CI 95%)          P value         
Age                                                                                                         1.07 (0.997-1.036)      0.098 
Sex                                                          0.528            0.398 
CHD                                                        0.950            0.004   
COPD                                                     0.153             2.039       
Obesity                                                   0.118             2.446 
Neoadjuvant therapy                               0.060            3.595  
Duration of surgery                                                                                1.002 (0.999-1.004)         0.197   
Type of anastomosis                              0.001***       22.866           
(hand-sewn vs. stapler)     
 Anastomotic leak                                    0.790            0.070 
Reoperation                                              0.150            2.108   
Intraoperative blood loss                                                                        1.000 (0.999-1.000)         0.658 
Minor postoperative complication         0.810             1.060   
(Clavien-Dindo I&II) 
Major postoperative complication          0.100             0.001 
(Clavien-Dindo III-V)   
Histology                                               0.310             1.034     
(SCC vs. adenocarcinoma) 
UICC tumor stage                                 0.002**          16.971           
, **  p<0.01,   p< 0.001 
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Table 20. Risk factors for survival after abdomino- thoracic resection for esophageal 
cancer- multivariate analysis 
                                                                                            Cox regression  
Parameter                                                 OR (CI 95%)                                      P value         
Type of anastomosis                                      0.165 (0.067- 0.409)                               <0.001 *** 
UICC tumor stage                                         1.371 (1.130- 1.663)                                 0.001***                           
*** p< 0.001 
 
 
 
 
 
 
 
 
 
Figure 3: Overall survival after abdomino- thoracic resection for esophageal cancer depending upon the type of 
anastomosis (p< 0.001, log rank test). 
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Figure 4: Overall survival after abdomino- thoracic esophageal resection for cancer depending upon UICC 
tumor stage (p=0.001, log rank test) 
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3.3. Impact of cervical anastomosis upon postoperative outcome after esophagectomy for 
cancer. 
 
When analyzing operative data and postoperative morbidity among the different types of 
esophagectomies (transhiatal esophagectomies with intraabdominal esophagojejunostomy, 
transhiatal esophagectomies with cervical esophagojejunostomy, abdomino- thoracic 
esophagectomies with intrathoracic anastomosis and abdomino- thoracic esophagectomies 
with cervical anastomosis), we observed that in patients subjected to cervical anastomosis the 
rate of respiratory complications was significantly higher (p< 0.001, OR=20.88, binary 
logistic regression), compared to patients subjected to intrathoracic or intraabdominal 
anastomoses.  
 
As described in table 12, patients subjected to cervical anastomosis (either in the frame of 
transhiatal or after abdomino- thoracic esophageal resection) suffered singnificantly more 
often from major and lethal postoperative complications (Clavien- Dindo grade III- V) in 
comparison to intrathoracic and intraabdominal anastomosis (p< 0.001). In the THE cervical 
subgroup 20 patients (66.7%) suffered from postoperative complications grade III-V, 
compared to 35 patients (67.3%) in the TAE cervical subgroup. Moreover, in the THE 
cervical subgroup, 16 patients (53.3%) experienced postoperatively respiratory complication, 
16 patients (53.3%) underwent reoperation, 7 patients (23.3%) suffered from palsy of the N. 
recurrens, whereas in the TAE cervical subgroup, the rates were 46.1% (24/52 patients), 
40.4% (21/52 patients), and 26.9% (14/52 patients), respectively. Furthermore, the 90-day 
mortality in the THE cervical subgroup was 11/30 (43.3%), while in the TAE cervical 
subgroup it was only 15.4% (8/52 patients). In summary, patients subjected to cervical 
anastomosis experienced significantly higher rates of major and lethal complications, 
significantly more respiratory complications, and palsies of N. recurrens. 
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3.4.1. Response to neoadjuvant therapy (NAT). 
  
We investigated whether the histological subtype influenced the response to neoadjuvant 
treatment (NAT) and its effect upon disease free interval (DFI) and overall survival (OS) in 
patients with esophageal cancer treated in our institution. 
 
Included into the study were patients undergoing esophageal resection in curative intention 
following NAT with a postoperative survival of at least 90 days. Indication for NAT was 
tumor stage ≥ T3 and/or N+ as diagnosed in preoperative endosonography (EUS). Excluded 
were patients in UICC stage IV, or no R0 resection. 
 
Out of 117 patients who underwent NAT, 3 groups were analyzed: group 1, "complete 
responders", if T0N0 tumor stage was diagnosed in the postoperative histopathological 
examination of the specimen (n= 26, 22.2%), group 2, "partial responders", if a less advanced 
tumor stage was postoperatively diagnosed in comparison to preoperative EUS staging (n= 
55, 47%) and group 3, "no responders", if no change or progression was observed (n= 36, 
30.8%). As mentioned before, until 2012, PLF protocol consisting of cisplatin, folic acid, 5-
fluorouracil (5-FU) was used.  In case of squamous cell carcinoma, simultaneous irradiation 
[45 Gy (1.5 per day)] was added. Since 11/2012, NAT consists of weekly doses of carboplatin 
and paclitaxel for 5 weeks and simultaneous radiotherapy (41.4 Gy in 23 fractions) followed 
by surgery after four weeks. 
 
72 out of the 117 patients (61.5 %) suffered from AC, whereas 45 patients (38.5%) from SC. 
3 tumors were located in the upper 1/3 of esophagus (n= 2.6%), 61 tumors in the middle 1/3 
of esophagus (n= 52.1%), and 53 tumors in the lower 1/3 of esophagus (45.3%). Table 21 
shows the correlation between histological subtype and response to NAT: the response of 
patients with SCC to neoadjuvant treatment was significantly higher in comparison to patients 
with adenocarcinoma of esophagus (p= 0.002, x² exact test).  
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Table 21. Response to neoadjuvant therapy (NAT) among patients with adenocarcinoma (AC) and 
squamous cell carcinoma (SC) of esophagus (n=117 patients) 
                                                        Adenocarcinoma          SCC                   Total               P value 
   Response                                                 72                         45                      117 
No response, n (%)                           30 (41.7%)               6 (13.3%)            36 (30.8%)         0.002** 
Partial response, n (%)                     31 (43.1%)              24 (53.3%)           55 (47%) 
Complete response, n (%)                11 (15.3%)              15 (33.3%)           26 (22.2%) 
 
** p<0.01 
 
 
3.4.2. Tumor disease free interval (DFI) and median overall survival (MS) depending on 
response to NAT. 
 
We analyzed the influence of response to NAT on tumor- free disease interval and median 
overall survival. Following parameters were included in the multivariate survival analysis: 
age, sex, presence of coronary heart disease or obstructive lung disease, obesity, response to 
NAT, tumor localization, histological subtype, intraoperative blood loss, anastomotic leak, 
major postoperative complications Clavien- Dindo grade III- IV. 
 
41 patients (35%) suffered from tumor progress in follow- up despite NAT and R0 esophageal 
resection. Median disease free interval (DFI) of group 1 (complete responders) was 34 months 
[9- 139], DFI of group 2 (partial responders) was 25 months [1- 134], and DFI of group 3 (no 
responders) was 13 months [0- 124]. Response to NAT was the only significant, independent 
factor that influenced DFI (p= 0.004, log rank test). Histological subtype and tumor 
localization did not significantly influence DFI (p= 0.85, and p= 0.64 respectively, log rank 
test). Whereas the difference in DFI depending on response to NAT was consistent if AC was 
the histological subtype (group 1: 11 patients, group 2: 30 patients, group 3: 30 patients, p = 
0.02, log rank test), the difference in DFI in the subgroup of patients with SC could not be 
shown (group 1, n=15 patients, group 2: 25 patients, group 3: 6 patients, p = 0.27, log rank 
test), due to the very high rate of response to NAT in the SCC subgroup (n=39, 86.7%). The 
DFI curves are given in figures 5- 7. 
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Interestingly, 6 out of 26 patients (23%) experienced tumor progress, despite initial complete 
response observed in the postoperative histopathologic specimen.  
 
 
 
Figure 5: Significant influence of response to NAT on disease free interval (n=117, p= 0.004, log rank 
test) 
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Figure 6: Significant influence of response to NAT on disease free interval in patients with AC (n=72, 
p= 0.02, log rank test) 
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Figure 7: Influence of response to NAT on disease free interval in patients with SC (n=45, p= 0.27, 
log rank test) 
 
 
Median survival of group 1 was 33 months [4- 139], 25 months [1- 134], and 14 months [4- 
124], respectively (p = 0.02, log rank test). The following parameters were included in the 
survival analysis: age, sex, presence of coronary heart disease or obstructive lung disease, 
obesity, response to NAT, tumor localization, histological subtype, intraoperative blood loss, 
anastomotic leak, major postoperative morbidity and reoperation. In the same line of 
evidence, NAT was the only significant, independent factor that influenced OS (p= 0.015) in 
the multivariate Cox regression analysis (tables 22- 23). The survival curves are given in 
figures 8- 10. 
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Table 22. Univariate survival analysis for patients subjected to NAT and esophageal 
resection (n=117) 
                                                              Log rank for                        Cox regression for 
                                                    categorical parameters            continuous parameters         
Parameter                                    P value              x ²                OR (CI 95%)          P value         
Age                                                                                                     1.025 (0.993-1.057)        0.124 
Sex                                                          0.721            0.127 
CHD                                                       0.349            0.004   
COPD                                                     0.427            0.630       
Obesity                                                   0.956            0.003 
Histological subtype                               0.805            0.061 
Response to NAT                                   0.016*          8.289  
Tumor localization                                 0.614            0.975 
 Anastomotic leak                                   0.149            2.080 
Reoperation                                             0.015*          5.860   
Intraoperative blood loss                                                                       1.000 (1.000-1.001)       0.127 
Major postoperative complication           0.874            0.025 
(Clavien-Dindo III -IV)   
*  p <0.05 
 
Table 23. Multivariate survival analysis for patients subjected to NAT and esophageal 
resection (n=117) 
                                                                                            Cox regression  
Parameter                                                 OR (CI 95%)                                    P value         
Response to NAT                                      0.615 (0.416- 0.909)                                      0.015 * 
Reoperation                                               1.671 (0.960- 2.909)                                      0.069                           
*  p <0.05 
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Figure 8: Significant influence of response to NAT on overall median survival (n=117, p= 0.016, log 
rank test) 
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Figure 9: Significant influence of response to NAT on overall median survival in patients with 
esophageal AC (n=72, p= 0.013, log rank test) 
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Figure 10: Influence of response to NAT on overall median survival in patients with SC (n=45, p= 
0.400, log rank test) 
 
As mentioned above, until 2012 patients with AC were subjected only to chemotherapy 
according to PLF protocol (n= 41). Up this point, combined chemoradiation according to 
CROSS protocol was given (n=31). The response to NAT was also compared among these 
subgroups. Despite the addition of radiation in the NAT, no significant difference in response 
rates was observed (p= 0.979, x² exact test). The response rates are given in table 24. 
 
Table 23. Comparison of response to NAT in patients with AC treated according to PLF vs. 
CROSS protocol 
                                                      PLF                   CROSS               Total                P value 
 Response                                       41                        31                      72 
No response, n (%)                    17 (41.5%)        13 (41.9%)            30 (41.7%)          0.979 
Partial response, n (%)              18 (43.9%)         13 (41.9%)            31 (43%) 
Complete response, n (%)          6 (14.6%)           5 (16.1%)            11 (15.3%)             
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Summarizing, our results highlight the different tumor biology among the two main 
histological subtypes of esophageal cancer. Patients with SC experienced better response rates 
in comparison to patients with AC, due to the higher radiosensivity of SC. The additional 
radiation preoperatively in patients with AC, according to CROSS protocol after 2012, did not 
significantly influence the response to NAT (p= 0.979, x² exact test). Response to NAT was 
the only significant, independent factor that influenced patient survival (p= 0.015, OR= 0.615, 
95% CI= 0.416- 0.909).   
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3.5. Role of surgical experience. 
We investigated whether surgical experience influences the postoperative outcome after 
esophagectomy for esophageal cancer. All esophagectomies in our surgical department were 
performed either by chief surgeon or by a senior surgeon. We divided the operations into 3 
groups: group 1: operations performed by chief surgeon, group 2: operations performed by 
experienced senior surgeons (>20 esophagectomies), and group 3: operations performed by 
senior surgeon (surgical experience <20 esophaegectomies).  
 
No statistical significance was observed regarding the postoperative morbidity comparing the 
different groups of surgeons (table 25). 
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Table 25. Esophagectomies for esophageal cancer (n= 320). Operative data and postoperative outcome 
depending on surgical experience 
                                   Chief surgeon       Senior surgeon          Senior surgeon        Total        P value 
                                                         >20 esophagectomies   <20 esophagectomies                        
                            
Parameters                  124 (38.8%)                    135 (42.2%)                       61 (19%)                 320 (100%) 
Duration of surgical          235 [77, 432]                281 [104, 675]                295 [161, 548]            257 [77, 675]        0.357  
procedure  
median [min., max.]   
 
Blood loss in ml                300 [5, 2500]                300 [20, 4000]               250 [50, 6000]            300 [5, 6000]         0.395 
median [min., max.]   
 
Number of dissected           17 [3, 65]                       16 [2, 62]                      18 [3, 47]                    17 [2, 65]              0.821 
lymph nodes                                        
median [min., max.] 
          
Minor postoperative              17 (13.7%)                   14 (10.4%)                    9 (14.8%)                   40 (12.5%)           0.604         
complications Clavien- Dindo 
Grade I-II, n (%)    
 
Major& lethal 
 postoperative                        46 (37.1%)                    60 (44.4%)                   21 (34.4%)                 127 (39.7%)         0.312 
complications Clavien- Dindo 
Grade III-V, n (%)    
Respiratory complications  
n (%)                                        38 (30.6%)                 42 (31.1%)                    16 (26.3%)                   96 (30%)            0.772 
Reoperation, n (%)                  34 (27.4%)                 46 (34%)                        22 (36%)                    102 (31.9%)         0.381  
Anastomotic leak, n (%)          13 (10.5%)                24 (17.8%)                      9 (14.8%)                    46 (14.4%)         0.246 
Anastomotic stricture, n (%)    11 (8.9%)                  14 (10.4%)                      5 (8.2%)                      30 (9.4%)           0.863 
Palsy of N. recurrens, n (%)       8 (6.5%)                   11 (8.1%)                       5 (8.2%)                      24 (7.5%)           0.863 
30- day mortality, n (%)             6 (4.8%)                   10 (7.6%)                       9 (14.8%)                    25 (7.8%)            0.06 
60- day mortality, n (%)             12 (9.6%)                 14 (10.7%)                    11 (18%)                      37 (11.6%)         0.211 
90- day mortality, n (%)             17 (13.7%)               22 (16.8%)                    14 (23%)                      53 (16.6%)         0.281 
Hospital stay (days)                    21 [8, 133]               22, [8, 198]                   21, [9, 127]                  22, [8, 198]           0.66    
median [min., max.]                                                                                                                    
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3.6. Predictors for major& lethal postoperative complications (Clavien- Dindo grade III- 
V), anastomotic leak, and overall patient survival 
 
The median overall survival was 17 months (0- 147 months, n=320). The 1-, 3- and 5 year 
survival was 65.2%, 41.7%´, and 30.7% respectively (figure 11). 
 
 
 
 
Figure 11: Overall patient survival (OS) after resection for esophageal cancer in UKS (n= 320 patients). 
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3.6.1. Predictors for major postoperative complications of grade III- V and anastomotic 
leak  
Female gender, anastomotic leak and respiratory complications were significant, independent 
factors for higher rate of major and lethal postoperative complications (Clavien- Dindo III- V) 
after resection for esophageal cancer in the multivariate regression analysis with p= 0.002, 
OR= 0.417, p< 0.001, OR= 0.028, and p< 0.001, OR= 0.121, respectively (table 26). 
 
Interestingly, anastomotic leak was significantly related with presence of COPD (p= 0.026, 
OR= 2.109, 95% CI= 1.096- 4.061), as shown in table 27. Neoadjuvant therapy, surgical 
experience, type of surgical procedure and type of anastomosis did not significantly influence 
the rate of anastomotic leak (p= 0.853, OR= 0.942, p= 0.274, OR= 1.264, p= 0.893, OR= 
1.023, and p= 0.471, OR= 0.772, respectively). 
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Table 26. Univariate and multivariate analysis of predictors of major& lethal 
postoperative complications (Clavien- Dindo III- V) after resection for esophageal 
cancer (n=320 patients, binary logistic regression) 
                                               Univariate analysis                      Multivariate analysis 
Parameter                              OR (CI 95%)            P value       OR (CI 95%)          P value 
Age                                          1.016 (0.993-1.039)           0.171  
Sex                                           1.992 (1.094-3.625)           0.024*         0.417 (0.199-0.873)        0.02* 
CHD                                         1.168 (0.679-2.012)          0.574  
COPD                                       1.264 (0.760-2.102)          0.366      
Obesity                                      1.033 (0.596-1.789)          0.908   
Neoadjuvant therapy                 0.604 (0.384-0.949)          0.029*         1.359 (0.767-2.408)        0.293 
Advanced tumor stage              1.150 (0.745-1.775)           0.529           
(UICC III& IV) 
Tumor localization                    0.865 (0.581- 1.287)         0.474     
Duration of surgery                   0.999 (0.997-1.002)           0.626      
Intraoperative blood loss          1.000 (0.999-1.000)           0.874      
Surgical experience                  1.000 (0.737-1.357)           1.000 
Type of operation                      1.142 (0.900-1.450)          0.275 
Anastomotic leak                       23.625 (8.207- 68.007)     <0.001***     0.028 (0.009-0.086) <0.001*** 
Respiratory complications         6.422 (3.789- 10.884)       <0.001***   0.121 (0.066-0.221)   <0.001*** 
* when p <0.05, *** when p< 0.001 
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Table 27. Univariate analysis of predictors of anastomotic leak after resection for 
esophageal cancer (n=320 patients, binary logistic regression) 
                                                                       Univariate analysis                         
Parameter                                                OR (CI 95%)         P value          
Age                                                           0.998 (0.968-1.030)           0.903  
Sex                                                            1.100 (0.481-2.518)           0.821        
CHD                                                         1.569 (0.774-3.180)          0.212  
COPD                                                       2.109 (1.096-4.061)          0.026*          
Obesity                                                     1.223 (0.585-2.560)          0.592   
Neoadjuvant therapy                                0.942 (0.504-1.761)          0.853        
Duration of surgery                                 1.000 (0.997-1.004)           0.862      
Intraoperative blood loss                         1.000 (0.999-1.001)           0.443      
Surgical experience                                 1.264 (0.831-1.925)           0.274 
Type of surgery                                        1.023 (0.735-1.423)          0.893 
Type of anastomosis                                0.772 (0.381-1.563)          0.471      
(hand-sewn vs. stapler) 
Tumor localization                                   1.487 (0.838-2.640)          0.175       
*  p <0.05 
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3.6.2. Predictors for overall patient survival (OS) after resection for esophageal cancer 
 
Advanced tumor stage, SC histological subtype and presence of major/ lethal postoperative 
complications Clavien- Dindo grade III- V were significant, independent factors for worse OS 
(p< 0.001, OR= 0.239, p= 0.028, OR= 1.506, and p= 0.005, OR= 0.582 respectively), as 
shown in tables 27 and 28, and figures 12 and 13.  
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Table 28. Univariate analysis of predictors of overall patient survival after resection 
for esophageal cancer (n=320 patients) 
                                                              Log rank for                       Cox regression for 
                                                    categorical parameters              continuous parameters         
Parameter                                    P value              x ²                 OR (CI 95%)          P value         
Age                                                                                                         1.012 (0.998-1.027)     0.092 
Sex                                                         0.679            0.171 
CHD                                                       0.251            1.317   
COPD                                                     0.102            2.680       
Obesity                                                   0.831            0.045 
Histology                                              0.015*            5.880     
(SC vs. AC) 
UICC tumor stage                              <0.001***       21.119 
Tumor localization                                 0.990            0.021  
Duration of surgery                                                                                1.001 (0.999-1.002)         0.265 
Type of operation                                 0.002**         14.888   
Intraoperative blood loss                                                                        1.000 (1.000-1.000)         0.230 
Anastomotic leak                                   0.885            0.021 
Respiratory complications                    0.007**         7.367 
Minor postoperative complications       0.965            0.002   
(Clavien-Dindo I&II) 
Major& lethal postoperative  
Complications                                      <0.001***    22.613 
(Clavien-Dindo III-V) 
Reoperation                                            0.001**      10.120   
*  p <0.05, **  p<0.01, ***  p< 0.001 
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Table 29. Multivariate analysis of predictors of overall patient survival after resection 
for esophageal cancer (n=320 patients) 
                                                                                   Cox regression  
Parameter                                                 OR (CI 95%)                                   P value         
Histology                                                    1.506 (1.045-2.170)                                        0.028* 
(SC vs. AC) 
Tumor stage                                               0.239 (0.113-0.505)                                       <0.001 ***           
Type of surgical procedure                        1.004 (0.551-1.830)                                          0.090           
Major& lethal postoperative  
complication                                              0.582 (0.398-0.851)                                         0.005 ** 
(Clavien-Dindo III-V) 
Respiratory complications                         0.935 (0.658-1.328)                                          0.706 
Reoperation                                                0.923 (0.651-1.310)                                          0.655  
*  p <0.05, **  p<0.01, ***  p< 0.001 
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Figure 12: Overall patient survival (OS) after resection for esophageal cancer  
depending on UICC tumor stage (n= 320 patients, p<0.001, OR=0.239, multivariate cox regression analysis). 
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Figure 13: Overall patient survival (OS) after resection for esophageal cancer  
depending on major and lethal morbidity (Clavien- Dindo grade III-V, n= 320 patients, p=0.005, OR=0.582, 
multivariate cox regression analysis). 
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4. Discussion: 
 
Aim of the present retrospective study was to assess the postoperative outcome and survival 
after surgery for esophageal cancer in our department in a time period from 2001- 2014. Our 
plan was to evaluate the results of surgical therapy and identify potential risk factors for 
worse postoperative outcome and overall patient survival (OS). 
 
4.1. Overall results: Advanced tumor stage, SC histological subtype and presence of major 
or lethal postoperative complications (Clavien- Dindo grade III-V) were significant, 
independent factors for worse overall patient survival (p<0.001, OR= 0.239, p=0.028, OR= 
1.506, and p=0.005, OR= 0.582, respectively). As expected, anastomotic leak and respiratory 
complications were significant, independent factors for higher rate of major or lethal 
postoperative complications Clavien Dindo grade III- V (p<0.001, OR= 0.028, and p< 0.001, 
OR=0.121, respectively).  
 
Our results confirm the results of the prospective, population- based study of Rutegard et al., 
who reported that surgical complications are independent predictors for worse long- term 
survival, even in patients who survived after the initial postoperative period 
34
.   However, our 
study indicates that major postoperative morbidity grade III- V according to Clavien- Dindo, 
not minor postoperative morbidity (Clavien- Dindo grade I& II), led to poor long- term 
survival and therefore confirm the statement of Luc et al., that major postoperative 
complications influence long- term survival after esophagectomy 
35
. 
 
 
4.1.1. Impact of type of surgery (transhiatal esophagectomy with cervical anastomosis) 
on postoperative outcome after resection for esophageal cancer. 
 
A significantly higher postoperative morbidity was observed, if transhiatal esophagectomy 
with cervical anastomosis was performed. The mortality and morbidity rates in patients with a 
cervical anastomosis were significantly increased in our series, reaching 36.7%, and 70% 
respectively. Moreover, approximately 25 % of the patients suffered from palsy of N. 
recurrens in the 6 months´ follow- up, a procedure- specific postoperative complication.  
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In 3 extensive series with 3129 patients undergoing surgery, the rate of anastomotic leak after 
cervical anastomosis ranged from 12% to 21% 
36-38
. The severity of anastomotic leak may be 
very disparate, from asymptomatic patients in type I leaks (localized leaks) to very severe 
symptoms such as systemic inflammatory reaction or septic shock in type IV leaks 
39
. This 
variation depends on the size of leak, how it spreads and the presence of ischaemia, necrosis 
of the gastric conduit 
40
, or presence of systemic inflammatory reactions. In the present study, 
anastomotic leaks were more frequently treated with reoperation in this group of patients 
(32/46, 69.6%).  Moreover, the number of patients who died within 90 days postoperatively 
was significantly increased, reaching up to one third of patients (36.7%). 
 
 
4.1.2. Impact of respiratory complications on postoperative outcome. 
Respiratory complications were summarized as minor postoperative morbidity (Clavien- 
Dindo grade I- II) in our cohort. Interestingly, we found no significant difference in the 
incidence of respiratory complications regarding transthoracic or intraabdominal esophageal 
resections, despite operative manipulation in the thorax within the transthoracic approach. 
This result is in accordance with the results of other studies, where minimally invasive 
esophagectomies did not lead to a lower rate of respiratory complications 
41, 42
. In minimally 
invasive esophagectomies, similarly to intraabdominal esophageal resections the thorax is not 
opened. However, a metaanalysis by Zhou et al. showed superiority of minimally invasive 
esophagectomy in reducing in -hospital mortality of patients with resectable esophageal 
cancer 
43
. 48 studies involving 14311 cases of resectable oesophageal cancer were included in 
the meta-analysis. Compared to patients undergoing open esophagectomy, patients 
undergoing minimally invasive esophagectomy had statistically decreased incidence of in-
hospital mortality (OR=0.69, 95%CI =0.55 -0.86). Patients undergoing minimally invasive 
esophagectomy also suffered from significantly less pulmonary complications (RR=0.73, 
95%CI = 0.63-0.86), pulmonary embolism (OR=0.71, 95%CI= 0.51-0.99) and 
tachyarrhythmia (OR=0.79, 95%CI = 0.68-0.92). Non-significant differences were observed 
among the included studies in the occurrence of anastomotic leak (OR=0.93, 95%CI =0.78-
1.11), or necrosis of the gastric conduit (OR=0.89, 95%CI =0.54-1.49) 
43
. 
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4.2. Special aspects concerning surgical technique: 
 
4.2.1. Hand- sewn versus stapler esophagogastric anastomosis after abdomino- thoracic 
resection for esophageal cancer. 
  
Special focus was given upon the impact of anastomotic technique (intrathoracic stapler 
versus hand- sewn esophagogastric anastomosis) after abdomino-thoracic esophagectomy for 
cancer. The heterogeneity of previously published studies, their contradictory results 
44-52
 and 
the fact that the use of stapler devices in the context of abdomino- thoracic resection for 
cancer increased substantially in our institution in the time period 2010- 2014 were the 
reasons to focus on this topic. Our data showed similar rates of revealed anastomotic leak and 
stricture between intrathoracic stapler and hand- sewn esophagogastric anastomosis. Female 
gender, presence of anastomotic leak and presence of respiratory complications were 
identified to be independent factors for higher rate of major/ lethal postoperative morbidity 
(Clavien- Dindo grade III-V). Furthermore, histological subtype (SC), advanced tumor stage 
(UICC grade III& IV) and presence of major/ lethal postoperative morbidity (Clavien- Dindo 
grade III-V) were identified to be statistically significant independent factors for worse 
overall patient survival in the multivariate analysis. Important to note, that histological 
subtype and tumor stage cannot be influenced by the surgeon, whereas the surgical 
performance belongs to the entire field of specialty.  
 
 Regarding anastomotic leak rates after abdomino- thoracic esophageal resection, our 
incidence of 12.5% is similar to other reported rates 
34, 53, 54
. Major/ lethal postoperative 
complications (Clavien- Dindo grade III- V) were significantly lower in the stapler 
anastomosis group, obviously due to the lower reoperation rate. Important to note, that in the 
hand- sewn anastomosis group, anastomotic leaks almost required reoperation (14/18 patients 
with anastomotic leak), contrary to the stapler anastomosis group, and thus leading to higher 
mortality (34.1% reoperation and 13.5% Clavien- Dindo V complications in the hand- sewn 
anastomosis group, compared to 8%, and 2% in the stapler group respectively). In the same 
line of evidence, no patient died from anastomotic leak in the stapler anastomosis group due 
to successful treatment with endoscopic stent insertion. Both, intraoperative blood loss and 
duration of surgery were comparable among both groups in contrary to the results of other 
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observational studies, claiming that stapler anastomosis is faster performed than hand- sewn 
anastomosis 
48
.  
 
There are numerous other studies comparing hand- sewn with stapled esophagogastric 
anastomosis (table 30). The majority consists in retrospective, non- randomized studies. 
Primary end points in these studies were anastomotic leak and stricture rate. The reported 
results are contradictory. Several reports showed no difference in anastomotic leak comparing 
both anastomotic methods 
44, 55-62
, while other reports demonstrated decreased anastomotic 
leak with stapler anastomosis 
49, 63-67
. Kim et al. concluded in their systematic review of eight 
randomized, controlled trials, that there was no significant difference in the anastomotic 
leakage or early mortality 
48
. One study demonstrated a difference in stricture rates, with 
fewer after hand-sewn anastomosis (9% vs. 40%, p= 0.003) 
47
. Two metaanalyses found no 
significant difference in the rate of anastomotic leak comparing both anastomotic 
techniques
48, 52
. However, retrospective and randomized trials vary substantially in the 
performed surgical technique, stapler size, end- to- end vs. end- to- side esophagogastric 
anastomosis, cervical vs. intrathoracic anastomosis, one- row vs. double- row anastomosis, or 
application of neoadjuvant therapy prior to surgery. Our analysis showed no significant 
differences concerning anastomotic leaks and strictures between both types of anastomosis, 
however both occurred less frequent (with a 50% reduction) after stapler anastomosis. 
Moreover, we should also notice, that 30- day mortality underestimates in- hospital mortality, 
as shown in previous reports 
68
. Our data also indicate, that 90- day mortality represents more 
accurately the in-hospital mortality. This was significantly reduced after stapler anastomosis 
(2 vs. 13.5%). Obviously, the stapler anastomosis is superior, providing better patient 
outcomes. 
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Table 30. Summary of non- randomized studies comparing hand- sewn with stapler 
esophagogastric anastomosis 
Study Number of 
patients 
 
Basic findings 
I. Retrospective studies 
Cooke et al. 67  1133 ↓ anastomotic insufficiency (AI) for stapler (OR=0.40, p<0.001), 
transhiatal esophagectomy with cervical esophagogastric anastomosis, 
side-to-side stapler anastomosis, 241 of patients had benign disease 
Zhu et al. 62 1194 ↓ AI for two- layer hand- sewn anastomosis (0% vs. 3.5%, p<0.001), 
groups not equal (1024 two-layer hand-sewn vs. 170 stapler 
anastomoses), cervical and intrathoracic anastomoses included in the 
study, preoperative radio-, chemotherapy was not given for all patients  
Kondra et al. 69 168 ↓ AI for stapler (13% vs. 27%, p=0.021), partially stapled (posterior 
stapled wall and anterior hand-sewn wall) anastomosis vs. hand-sewn 
cervical anastomosis 
Blackmon et al. 70 214 ↓ anastomotic strictures and dysphagia for stapler (OR=3.39), 214 
intrathoracic anastomoses included in the study, 3 groups: 44 side-to-
side stapler vs. 147 circular stapler vs.23 hand- sewn anastomoses, 
propensity-matching 
Viklund et al. 61 275 No difference among both anastomotic methods, different type of 
surgery and localization of the anastomosis, anastomotic methods not 
described 
Ercan et al. 44 170 No difference in AI, ↓ anastomotic strictures for stapler (88% vs. 63%, 
p<0.001), 86 modified Collard esophagogastric cervical (partially 
stapled, partially hand-sewn anastomotic technique, terminalized, 
semimechanical, side-to-side cervical esophagogastrostomy) vs. 188 
handsewn cervical anastomoses, propensity-matching 
Furukawa et al. 64 31 No difference among the three anastomotic methods, 3 groups: 11 
triangular, with TA-30 liner stapler vs. 8 with circular stapler vs. 12 
handsewn- cervical anastomoses 
Casson et al. 56 91 No difference among both anastomotic methods, (7.9% stapler vs. 
22.6% hand-sewn, p=0.08), 53 hand-sewn vs. 38 partially cervical 
esophagogastric stapler anastomoses 
Singh et al. 66 93 ↓ AI for stapler (3% vs. 23%, p<0.05), ↓ anastomotic strictures for 
stapler (18% vs. 58%, p<0.05), 67 transhiatal and 26 McKewon 
esophagectomies included in the study, 43 hand-sewn vs.16 partially 
stapler (modified Collard)  vs. 34 linear stapler cervical anastomoses 
Honkoop et al. 71 269 ↑ anastomotic strictures for stapler (48% vs. 35%, p=0.04), 269 
transhiatal esophagectomies with cervical anastomosis included in the 
study, 114 one-layer hand-sewn vs. 154 circular stapler cervical 
anastomoses 
Mc Manus et al. 49 221 ↓ AI for stapler (7.1% vs. 17.2%, p<0.05), ↑anastomotic strictures for 
stapler (15.3% vs. 2.7%, p<0.02) 
Sugimachi et al. 60 40 No difference among both anastomotic methods, 12 hand-sewn vs. 17 
―Russian‖ stapler vs. 11 ―American‖ stapler 
Present study 176 Reduction of AI among both anastomotic methods (8% vs. 14.3%, 
p=0.22), 126 hand-sewn vs. 50 circular stapler intrathoracic 
anastomoses 
 
II. Non-randomized prospective studies 
Fok et al. 57 785 No difference among both anastomotic methods 
Lam et al. 59 411 No difference among both anastomotic methods 
Peracchia et al. 65 242 ↓ AI for stapler (4.2% vs. 17.9%, p=0.013) 
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Wong et al. 55 174 
 
 
No difference in AI   
↑ anastomotic strictures with stapler (11.3% vs. 5.6%, p not referred) 
III. Meta-analyses 
Urschel et al. 45  5 randomized 
controlled trials 
No difference among both anastomotic methods 
Kim et al. 48 8 randomized 
controlled trials 
No difference among both anastomotic methods 
Honda et al. 52 12 randomized 
controlled trials 
No difference in AI (OR=1.02) 
↑ anastomotic strictures with stapler (OR= 1.67) 
↓ duration of surgical procedure (mean: - 15.3 minutes) 
 
An important methodological advantage of this comparison is the qualitative homogeneity of 
the included patients. We chose to include into the analysis only patients subjected to open 
Ivor- Lewis abomino- thoracic esophageal resection with intrathoracic anastomosis. The 
therapeutic protocol used in our department was also standardized and given in detail. An 
esophagogastroduodenoscopy was routinely performed in all of our patients to control the 
anastomosis in the 6 months’ follow- up. We did not analyze only the rate of anastomotic 
leak; a thorough comparison of various parameters including intraoperative blood loss, 
duration of surgical procedure, number of reoperations and 30-, 60- and 90- day mortality 
rates was performed.  
 
The paramount methodological disadvantage of the present study is the retrospective non- 
randomized character. Furthermore, the number of hand-sewn and stapler esophagogastric 
anastomoses was not equal (126 vs. 50). The majority of esophagogastric anastomoses were 
hand-sewn until May 2012. From this time point, most of the anastomoses were performed 
using a 25 mm circular stapler in our institution. A prospective randomised trial is therefore 
more appropriate to draw more valid conclusions and answer the question which anastomotic 
method is better. 
 
4.2.2. Role of postoperative radiologic examination and endoscopy in the detection and 
management of anastomotic leak.  
 
In a prospective, controlled study, Schaible et al. suggested superiority of endoscopy to 
radiographic diagnosis of potential anastomotic leak after esophageal reconstruction 
72
. The 
authors claim, that radiologic contrast swallow in the early postoperative days is often not 
feasible, has no further relevance, and therefore should be replaced by endoscopy. Contrary to 
this claim, we left the nasogastric tube routinely for 5 days postoperatively. If the anastomosis 
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was patent in the postoperative radiographic control at the fifth postoperative day, nasogastric 
tube was removed and enteral feeding with liquids was started. Postoperative chest X- rays 
were performed before and after removing the intraoperatively placed chest tubes. From our 
data, we cannot show if there is additional benefit from performing the gastrografin swallow, 
because this radiologic examination was always performed.   
 
Postoperative endoscopy played an important role in the management of anastomotic leak. In 
the stapler anastomosis group, anastomotic leaks were successfully endoscopically treated. In 
the hand- sewn anastomosis group, anastomotic leaks were treated mainly with reoperation. 
Consequently, 90 days´ mortality (Clavien- Dindo grade V complications) and overall 
survival was statistically significantly different among both anastomotic methods. Dasari et 
al. in their review of 27 case series (340 patients) recommend esophageal stent insertion as 
treatment option in the management of anastomotic leak with limited mediastinal or pleural 
contamination 
73
. If we focus on the abdomino- thoracic esophageal resections performed in 
our department, 50 stapled and 126 hand- sewn anastomoses were performed. 4 patients (8%) 
after stapler anastomosis suffered from anastomotic leak, of whom only one was reoperated. 
On the contrary, 18 patients (14.3%) after hand- sewn anastomosis suffered from anastomotic 
leak, of whom 14 were reoperated. Our results confirm that less reoperations obviously led to 
lower 90 days´ mortality and consequently increased patient overall survival in the stapler 
anastomosis group. As previously mentioned, endoscopy was performed in the 6 months´ 
follow- up to control potential local tumor recurrence and treat potential anastomotic 
strictures with balloon dilatation.   
 
4.2.3. Transthoracic vs. transhiatal resection for esophageal cancer. 
 
 Several studies compare transthoracic to transhiatal esophagectomy 
74, 75
. In a randomized- 
controlled trial by Omloo et al. 
74
, no statistical advantage in overall 5-year survival could be 
found in patients with adenocarcinoma of the middle /distal esophagus (AEG I/ II) subjected 
to extended transthoracic compared to patients subjected to transhiatal esophageal resection. 
However, in contrast to transhiatal esophageal resection, extended transthoracic 
esophagectomy for type I esophageal adenocarcinoma shows an ongoing trend towards better 
5-year survival, reaching nearly 36% in a recently published trial 
74
. Moreover, patients with a 
limited number of positive lymph nodes in the resection specimen seemed to benefit from an 
77 
 
 
extended transthoracic esophagectomy 
74
. Two meta-analyses by Yang et al. and Boshier et al. 
76
 could also not demonstrate statistically significant differences in survival and postoperative 
morbidity and mortality in patients with AEG undergoing transthoracic or transhiatal 
resection 
75
. However, the type of the selected procedure depends on the localization of the 
tumor, accounting for a significant selection bias, when comparing TTE to THE without 
considering the localization of the tumor. Moreover, the lymph nodes of lower mediastinum 
are often resected when performing THE, so that the performed lymphadenectomy is more 
extended than the standard D2 lymphadenectomy. Mönig et al. could demonstrate, that the 
main topographical distribution of lymph node metastasis in adenocarcinoma of 
gastroesophageal junction is towards the abdomen and the lower mediastinum. In 50 
specimens, 1730 lymph nodes were evaluated regarding metastatic infiltration. Lymph node 
metastases of the lower mediastinum were found in 24% of type I carcinoma, in 11% of type 
II carcinoma and in 13% of type III carcinoma, whereas the lymph nodes of the upper 
mediastinum were tumor free in all patients with transthoracic en bloc resection and 2-field 
lymphadenectomy (n = 13). In all cases with lymph node metastasis abdominal lymph nodes 
were infiltrated independently from the localization of the primary tumor 
77
.  
 
179 abdomino- thoracic esophageal resections and 59 transhiatal esophagectomies were 
performed in our department. Our data demonstrate similar postoperative outcome comparing 
both surgical procedures. We observed no statistically significant difference regarding 
anastomotic leaks, major surgical complications, 90 day mortality or overall patient survival 
(p= 0.107, 0.192, 0.270, and 0.51, respectively). Respiratory complications appeared more 
frequently in the ―abdomino- thoracic esophageal resection‖ group, though not reaching 
statistical significance (p= 0.06, chi square test). 
 
4.2.4. Extended LN- dissection.  
In Japan, extensive lymph- node dissections with curative intent are widely performed, 
including the upper and middle mediastinal lymph nodes (two- field lymphadenectomy) or 
occasionally three- field lymphadenectomy including also the cervical lymph nodes 
78
. The 
incidence of squamous- cell esophageal cancer is higher in Asia compared with Western 
countries, which could explain why three- field lymphadenectomies are more often performed 
in Japan in association with R0 resection. Interestingly, Igaki et al. suggested that three- field 
78 
 
 
lymphadenectomy should also be performed for squamous cell carcinomas of the lower 
thoracic esophagus 
78
. A prospective randomized trial showed high rates of neck recurrence in 
patients with SCC, supporting D3 lymphadenectomy in this group of patients 
79
.  Lerut et al. 
showed, that overall morbidity was 58% and 5 years´ overall survival was 41.9% after three-
field lymphadenectomy 
80
. Several meta-analyses suggested extended D3 lymphadenectomy, 
especially for tumors with lymph node metastasis 
81
, however with higher anastomotic leaks 
and N. recurrens palsy 
82
.  The role of 3-field lymphadenectomy in distal third esophageal 
adenocarcinoma remains a case of controversy 
80
. 
Extended lymph node dissection is performed according to the Japanese society for gastric 
cancer for Siewert type II adenocarcinoma of the esophagogastric junction 
28
. Mine et al. 
investigated the lymph node involvement and prognosis in patients with Siewert type II 
cancers treated by surgical resection, with regard to lymphadenectomy around the left renal 
vein 
83
. Out of 150 patients with type II esophagogastric adenocarcinoma, 94 had left renal 
vein lymphadenectomy. In these patients, the incidence of involvement was 17 %, and the 5-
year survival rate was 19 %. Multivariate analysis showed left renal vein lymphadenectomy to 
be an independent prognostic factor in patients with histopathological tumor category T3-4 
(OR= 0.51, 95% CI= 0.26- 0.99, p= 0.048) 
83
. The authors concluded that left renal vein nodal 
involvement is similar to that seen along the splenic artery, in the lower mediastinum and 
celiac trunk, with similar impact on patient survival.  
Yamashita et al. explored the extent of lymphadenectomy in 225 patients with AEG II tumors 
84
. They also dissected the para- aortic lymphatic nodal station 16a2 in 73 patients and the 
nodal station 16b in 38 patients. The incidence of positive lymph nodes was 11% for 16a2 and 
18 % for 16b. The 5- year survival rate in patients with positive lymph nodes was 12.5% for 
16a2 and 0% for 16b. It is subsequently questionable, whether a more extended 
lymphadenectomy with dissection of para- aortic nodes should be routinely performed, due to 
the low incidence and the low survival rate, as concluded by the authors 
85
.   
88 patients with AEG II tumor were operated in our department with a median survival of 23 
months. As previously mentioned, we routinely performed the D2 lymphadenectomy. 
Moreover, lymph nodes of lower mediastinum were also resected when performing THE. 
Postoperative lymph node status significantly influenced overall patient survival (p< 0.001, 
log rank test).    
79 
 
 
There is only one report (n= 4 cases) regarding salvage lymphadenectomy for recurrent 
esophageal cancer after lymphadenectomy 
85
. In this study, salvage esophagectomy was 
indicated for locoregional recurrence without distant metastases after failed definitive 
chemoradiation (RCT) 
85
. In case 1, right supraclavicular lymph node was tumor infiltrated 
and R0 resection was carried out; the patient was alive without recurrence (follow- up 18 
months). In case 2, metastases in the left cervical paraesophageal and the left supraclavicular 
lymph nodes were found; residual tumors were R1 in both lesions. The patient was alive 
despite esophageal recurrence (follow- up 32 months). In case 3, a lymphadenectomy was 
performed on his thoracic para-aortic lymph nodes; however, the tumor was removed 
incompletely, and the patient died 4 months after salvage lymphadenectomy from tumor 
disease progression. In case 4, a subcarinal lymph node was considered metastatic, and was 
dissected but turned out to be tumor free. The patient died 17 months postoperatively from 
pneumonia. The authors concluded, that their experiences suggest that some patients may 
survive relatively long with salvage lymphadenectomy 
85
.  
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4.3. Role of neoadjuvant therapy or definitive chemoradiation on postoperative outcome 
 
4.3.1. Impact of histological subtype on response to neoadjuvant therapy (NAT), disease 
free interval (DFI) and OS. 
 
In addition, special attention was given in the impact of histological subtype upon response to 
NAT, DFI, and OS.  
 
Neoadjuvant chemoradiation became a standard part of the multimodal therapy of esophageal 
cancer, because of the results of large randomized trials that reported improved long- term 
outcomes 
32, 86-92
. The Chemoradiation for Oesophageal Cancer Followed by Surgery Study 
(CROSS) Group, included patients with either esophageal adenocarcinoma or squamous cell 
carcinoma who were clinical stage T1N1 or T2-3, N0-1, and showed that squamous cell 
carcinoma hat more favorable outcomes compared to esophageal adenocarcinoma 
32
. 
Consequently, patients with both histological subtypes (adenocarcinoma of esophagus, 
squamous cell carcinoma of esophagus) are currently subjected to the same neoadjuvant 
therapy regardless of histological subtype.  
 
However, Deng et al. separated the patients with SC and the patients with AC concerning 
neoadjuvant therapy. After conducting a meta- analysis, they suggested neoadjuvant 
chemoradiation as standard preoperative treatment strategy for locally advanced esophageal 
SC. In patients with esophageal AC, the authors concluded, that neoadjuvant chemotherapy 
alone may be the best preoperative treatment strategy to avoid the adverse effects of 
radiotherapy 
93
. Contrary to this assumption, Alnaji et al. supported the neoadjuvant 
chemoradiation for esophageal AC, and demonstrated the value of pathologic complete 
response in long- term outcomes.
94
  Hoeppner et al. supported chemotherapy alone for 
patients with locally advanced esophageal AC in their retrospective study, claiming, that there 
was no survival benefit in comparison to patients treated with neoadjuvant chemoradiation, 
despite better histologic response after chemoradiation 
95
. The additional irradiation 
preoperatively in our patients with locally advanced AC, according to CROSS protocol after 
2012, did not significantly influence the response to NAT (p= 0.979, x² exact test). Moreover, 
our study demonstrates, that not only complete response, but also partial response to NAT 
81 
 
 
contributes significantly to overall patient survival after esophageal resection for cancer, 
regardless of histological subtype (p= 0.015, OR= 0.615, 95% CI= 0.416- 0.909).   
 
Concerning overall survival benefit of patients receiving neoadjuvant therapy, we refer to the 
metaanalysis of Gebski et al., where the influence of neoadjuvant chemoradiation on survival 
rates of patients with squamous- cell carcinoma and the influence of preoperative 
chemotherapy on survival of patients with adenocarcinoma of the esophagus were separately 
examined (10 randomized studies with 1209 patients and 8 randomized studies with 1724 
patients, respectively) 
96
. This metaanalysis reported significant survival benefit (13% 
difference after 2-years) in case of squamous- cell carcinoma, but not in case of esophageal 
adenocarcinoma.  
 
The favorable effects of neoadjuvant therapy were shown in a Cochrane database review from 
2013, where 14 randomized controlled trials with a total of 2422 eligible patients were 
analysed. Perioperative chemoradiation was associated with longer disease-free survival, 
higher rates of R0 resection, and more favorable tumor stage at the time of resection, while 
there was no association to perioperative morbidity and mortality for resectable 
adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus 
97
. In our 
study, response to NAT was the only independent factor that influenced disease free interval 
and overall patient survival regardless of histological subtype. 
A significant restriction of our analysis, apart from its retrospective character, is the relative 
small number of study population. From 320 patients operated in our department from 2001- 
2014, only 117 patients met the inclusion criteria. We excluded patients who died within the 
first 90 days postoperatively, or suffered from UICC Stage IV esophageal cancer, to 
investigate tumor progress and long- term survival.  
In addition, the need for tailored neoadjuvant therapy depending on histological subtype is 
demonstrated in the present study. We expect therefore with great interest the results of the 
ESOPEC trial, a prospective randomized controlled multicenter phase III trial comparing 
perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS 
protocol) in patients with adenocarcinoma of the esophagus 
98
. 
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Previous observational studies have reported that neoadjuvant therapy did not lead to 
increased surgical morbidity 
48
. Mungo et al. compared 30- day mortality and postoperative 
morbidity after esophagectomy in patients who had received neoadjuvant therapy and patients 
without neoadjuvant therapy in a time-period from 2005- 2011 
99
. They concluded that the 
incidence of postoperative complications was similar in both groups. However, they reported 
less blood loss and thromboembolic events in the ―surgery- alone‖ group (5.71% vs. 8.27%, 
p= 0.027; 6.89% vs. 10.57%, p= 0.004).  
 
Interestingly, 6 out of 26 patients (23%) experienced tumor progress, despite initial complete 
response observed in the postoperative histopathologic specimen. 2 out of 6 patients suffered 
from esophageal adenocarcinoma. 
 
The impact of neoadjuvant therapy on postoperative outcome after esophageal resection was 
assessed in a European multicenter study 
100
. 2944 patients treated for esophageal cancer 
between 2000 and 2010 in 30 European centers were included in this study. There was no 
difference in anastomotic leak among patients subjected to neoadjuvant therapy or patients 
without neoadjuvant therapy. Our study basically confirms these results. Neoadjuvant 
therapy, as well as surgical experience, type of surgical procedure or type of anastomosis did 
not significantly influence the rate of anastomotic leak (p= 0.853, OR= 0.942, p= 0.274, OR= 
1.264, p= 0.893, OR= 1.023, and p= 0.471, OR= 0.772, respectively). 
 
4.3.2. Role of definitive chemoradiation (RCT) in esophageal cancer.  
 
In view of the high morbidity after esophageal surgery for cancer (44.7% major postoperative 
morbidity of grade III-V after Clavien- Dindo classification in our patients), alternative 
therapeutic strategies could be considered. Especially for patients with locally advanced SCC 
of the upper 1/3 of esophagus and comorbidities, it was suggested to apply definitive RCT for 
patients not suitable for surgery as first line treatment and salvage surgery only in cases 
without response or with locoregional recurrence after definitive RCT for this group of 
patients 
101
. There are two randomized controlled trials comparing the benefit of adding 
surgery to definitive RCT 
101, 102
. Only patients with squamous cell carcinoma of the 
esophagus were included. The study of Bedenne et al. randomized patients with response after 
RCT either to a surgery or an observation group 
103
. 259 patients were evaluated (129 
83 
 
 
surgical, 130 definitive RCT; 11% adenocarcinoma). Median survival in the surgical and non-
surgical groups was 17.7 months and 19.3 months, respectively, and 2-year overall survival 
was 34% versus 40%, respectively (OR=0.90, p=0.44). In the surgical group, improved 
locoregional control and less palliative procedures (such as stent insertion) were found. 
Mortality analyzed at 90 days was 9.3% in the surgical group versus 0.8% in the non-surgical 
group. The fact that improved locoregional control in the surgical group did not lead to an 
increase in overall survival implies the difficulty to adequately stage patients before treatment 
and the biological heterogeneity inherent to esophageal cancer. 
  
The study of Stahl et al. adopted induction chemotherapy prior to RCT in an effort to decrease 
formation of remnant metastases 
101
. This study randomized 172 patients (86 to RCT followed 
by surgery versus 86 treated with definitive RCT). The results showed better locoregional 
disease control with surgery and longer disease-free survival with surgery compared to 
observation after definitive chemoradiation (64% versus 41% at 2 years; p= 0.003). However, 
in contrast to the Bedenne trial, the Stahl trial (which randomized all patients rather than 
responders only) demonstrated a survival advantage in the surgery group (31% versus 24% at 
3 years; p= 0.02). This study also found a significant increase in treatment-related mortality in 
the surgical group (12.8% versus 3.5%; p=0.03). An interesting finding on the sub-group 
analysis was that non-responders with (R0) resection reached 32% 3 -year survival. This 
markedly contrasted to responders who achieved more than 50% 3 -year survival regardless 
of the treatment modality. 
Markar et al. reported that salvage esophagectomy (SALV) is associated with poor short-term 
outcomes when compared to scheduled esophagectomy following neoadjuvant RCT (NCRS). 
This metaanalysis included eight studies comprising 954 patients; 242 (SALV) and 712 
(NCRS). SALV was associated with a significantly increased incidence of post-operative 
mortality (9.5 vs. 4 %; pooled odds ratio [POR] = 3.02; p < 0.001), anastomotic leakage (24 
vs. 15 %; POR = 1.99; p = 0.005), pulmonary complications (30 vs. 17 %; POR = 2.12; 
p < 0.001), and an increased length of hospital stay (weighted mean difference = 8.3 days; 
95 % CI 7.08–9.5; p < 0.001) 102.  
In our study, we did not include patients who received definitive RCT for squamous- cell 
esophageal cancer. However, the postoperative morbidity and the overall survival following 
transhiatal esophagectomy with cervical anastomosis with advanced tumor stage was 
84 
 
 
disappointing. Retrospectively, we may reconsider, that these patients would probably benefit 
more from a definitive RCT instead of surgery. 
Whether a definitive RCT compared to surgical resection results in less mortality, morbidity, 
and longer survival for older patients with esophageal cancer, was also subject to 
investigation. Morita et al. retrospectively explored this issue in a total of 1.002 patients with 
thoracic esophageal cancer undergoing esophagectomy. Three groups were formed: I (≤ 74 
years old, n=898); II (75-79 years, n=81); and III (≥ 80 years, n=23). Historical changes were 
related to as a first (1964-1989) and a second period (1990-2011). The morbidity rates were 
40%, 41% and 26% in the respective groups. Pulmonary complications decreased historically 
in groups II and III (36% to 15% and 43% to 0%, respectively). The mortality was higher in 
the older groups (4.8%, 8.6% and 13.0%, respectively); however, there was a marked 
historical decrease in groups II (18.2% to 5.1%) and III (28.6% to 6.3%). The 5-year survival 
improved from 5% to 35% in group II and from 0% to 17% in group III. They concluded that 
the outcomes of esophagectomy for elderly patients have markedly improved over time 
104
. 
The postoperative results after resection for esophageal cancer in older patients were 
comparable to those obtained in younger patients in our study. The preoperative age of 
patients should not be considered a contraindication to surgery according to our results. 
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4.4. Pros and Cons of retrospective studies. 
  
Our study is a retrospective cohort study; a major limitation of retrospective studies are 
significant biases which may have affected the results. Among these biases that may put in 
doubt the results of this type of study are the selection bias and the misclassification or 
information bias. Selection bias is a statistical bias in which there is an error in choosing the 
individuals or groups to take part in a scientific study. Information bias (epidemiology) means 
bias arising in a clinical study because of misclassification of the level of exposure to the 
agent or factor being assessed and/or misclassification of the disease or other outcome 
parameters 
105, 106
. Furthermore, exposure or outcome assessment cannot directly be 
controlled, but depends upon accurate record-keeping. Retrospective studies can require very 
large sample sizes, if rare events are examined 
107
.  
 
On the other side, important advantages of observational studies are, that they are conducted 
on a smaller scale,
 
they typically require less time to complete, they are better in comparison 
with prospective studies for analyzing multiple factors, and they can potentially address rare 
diseases, which would require extremely large cohorts in prospective studies. Retrospective 
studies are especially helpful in addressing diseases of low incidence 
107
. Retrospective 
studies are also less expensive than prospective studies, because the resources are mainly 
directed at collection and statistical analysis of data only. 
To assess the OS we selected patients operated until 31.12.2014; in order to be able to use 
censored data, we accept the hypothesis that censoring is independent or unrelated to the 
likelihood of developing the event of interest. This is called non-informative censoring  
108
. 
Appropriate use of the Kaplan-Meier estimation relies on the assumption that censoring is 
independent of the likelihood of developing the event of interest and that survival 
probabilities are comparable in participants who attend early and later into the study. When 
comparing several groups, it is also important that these assumptions are applied in each 
group and that censoring is not more likely in one group than another 
108
. 
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